Market Outlook

By 2035, the U.S. Outpatient Gastroenterology Devices Market is expected to reach approximately USD 17.22 billion, expanding at a CAGR of 8.45% during the forecast period 2026–2035. The market is estimated at USD 7.65 billion in 2025, with historical analysis covering 2021–2024. Values in this report are expressed in USD billions.

For market-sizing purposes, outpatient gastroenterology devices include capital equipment, reusable and single-use endoscopes, endoscopic visualization systems, endotherapy devices, gastrointestinal diagnostic and functional testing systems, capsule endoscopy technologies, endoscope reprocessing equipment, infection-prevention products, and software or artificial-intelligence tools directly supporting outpatient GI procedures. The scope covers ambulatory surgery centers, hospital outpatient departments, physician-owned endoscopy centers, office-based gastroenterology facilities, and outpatient specialty diagnostic centers. Professional fees, facility-service revenue, pharmaceuticals, pathology services, laboratory testing, and devices used predominantly for inpatient abdominal surgery are excluded.

The U.S. outpatient gastroenterology device ecosystem is benefiting from a structural change in digestive disease care rather than simply higher procedure volumes. Colonoscopy, upper gastrointestinal endoscopy, polypectomy, endoscopic mucosal resection, endoscopic ultrasound, selected ERCP procedures, capsule endoscopy, motility testing, hemostasis, stricture treatment, stent placement, and increasingly sophisticated therapeutic procedures are being organized around shorter-stay and ambulatory clinical pathways. This changes procurement economics because an outpatient GI facility must combine high procedure throughput with reliable visualization, rapid room turnover, predictable scope availability, efficient reprocessing, low infection risk, and disciplined cost per case.

The market also has one of the strongest recurring-revenue profiles within outpatient medical devices. Capital processors, light sources, imaging platforms, automated endoscope reprocessors, drying cabinets, and procedure-room infrastructure create an installed base, while biopsy forceps, snares, guidewires, injection needles, clips, retrieval devices, dilation products, hemostasis technologies, electrosurgical accessories, stents, valves, tubing, cleaning supplies, and other single-use components create recurring procedure-linked revenue. Artificial intelligence is adding another monetization layer through lesion-detection software, image-analysis functionality, workflow applications, and data-enabled quality improvement.

The historical market is estimated to have increased from approximately USD 5.34 billion in 2021 to USD 5.88 billion in 2022, USD 6.45 billion in 2023, and USD 7.03 billion in 2024, before reaching USD 7.65 billion in 2025. The 2021–2025 expansion reflects recovery of elective endoscopy following pandemic-era disruption, normalization of colorectal screening, increasing ASC capacity, replacement of aging endoscopy towers, growth in therapeutic accessories, higher utilization of advanced imaging, and commercial adoption of AI-supported colonoscopy.

The next phase of growth will be more technology intensive. The strongest value creation is expected in AI-assisted colonoscopy, next-generation HD and 4K visualization, image-enhanced endoscopy, advanced resection and closure technologies, EUS-guided intervention, single-use endoscopy for selected procedures, automated reprocessing and traceability, and devices capable of moving procedures from higher-cost hospital environments into efficient outpatient settings. The result is a market in which growth is determined not only by the number of endoscopies performed, but by the amount of technology and disposable-device value captured during each outpatient episode.

 

Introduction

According to the U.S. Outpatient Gastroenterology Devices Market Report, gastroenterology is exceptionally well suited to outpatient care because a substantial proportion of diagnostic and therapeutic GI procedures can be completed without an overnight stay. Colonoscopy and esophagogastroduodenoscopy remain foundational procedures, but the outpatient GI suite is increasingly becoming a platform for polypectomy, endoscopic tissue resection, bleeding control, stricture dilation, foreign-body removal, lesion marking, luminal stenting, EUS-guided diagnostics, bariatric endoscopy, motility assessment, and selected advanced interventions.

The underlying U.S. infrastructure is substantial. Approximately 6,436 Medicare-certified ambulatory surgery centers were operating in 2024, compared with 5,760 in 2019. About 1,208 facilities billing fee-for-service Medicare were classified as single-specialty gastroenterology ASCs in 2024, accounting for approximately 21% of Medicare-billing ASCs and making gastroenterology one of the two most common single-specialty ASC categories. Multispecialty facilities with a gastroenterology component further expand the addressable outpatient infrastructure.

GI procedures also occupy an unusually large share of ASC activity. Among the highest-volume fee-for-service Medicare ASC procedures in 2024, colonoscopy with snare lesion removal represented approximately 8.0% of volume, upper GI endoscopy with biopsy approximately 7.3%, colonoscopy with biopsy approximately 6.4%, high-risk colorectal screening approximately 2.3%, routine colorectal screening approximately 1.6%, and diagnostic colonoscopy approximately 1.1%. Combined with additional upper-GI procedures, the GI codes appearing among the leading ASC procedures represented at least one-quarter of total Medicare ASC procedure volume. This degree of procedure concentration gives gastroenterology device manufacturers a comparatively direct link between installed-base penetration and recurring consumable revenue.

The clinical demand pool remains large. The U.S. is expected to record approximately 154,270 new colorectal cancer cases and 52,900 colorectal cancer deaths in 2025. Screening penetration is meaningful but incomplete: in 2023, approximately 63.5% of adults aged 45–75 were up to date with colorectal cancer screening, while about 53.4% reported colonoscopy within the recommended ten-year interval. The gap between eligible and screened populations continues to support long-term colonoscopy demand, particularly following the expansion of routine screening eligibility to adults beginning at age 45.

Beyond cancer screening, outpatient GI facilities manage a broad burden of reflux disease, inflammatory bowel disease, gastrointestinal bleeding, dysphagia, Barrett’s esophagus, polyps, diverticular disease, motility disorders, chronic constipation, pancreatic and biliary disease, and obesity-related gastrointestinal conditions. These indications generate a mix of repeat diagnostic procedures and increasingly device-intensive therapeutic interventions.

The market is therefore less exposed to a single technology cycle than narrower medtech categories. A gastroenterology ASC may replace imaging processors every several years, scopes according to utilization and maintenance requirements, reprocessing infrastructure as standards evolve, and disposable accessories continuously. Manufacturers with broad portfolios can monetize multiple steps in the same patient episode, while specialist companies can secure attractive niches through superior lesion detection, closure, hemostasis, resection, motility testing, capsule diagnostics, or infection-prevention technologies.

From 2026 through 2035, procurement decisions will increasingly be made around cost per completed procedure, adenoma-detection support, room turnover, reprocessing labor, scope repair burden, infection-control assurance, accessory utilization, interoperability, uptime, training requirements, and reimbursement economics. The outpatient winner will not necessarily be the device with the highest technical specification. It will be the platform that improves clinical consistency while allowing physicians and facilities to process more appropriate cases without proportionately increasing staffing, capital complexity, or operational risk.

 

Key Market Drivers: What Is Accelerating the U.S. Outpatient Gastroenterology Devices Market?

The first major driver is the scale and recurring nature of colorectal cancer screening. Colonoscopy occupies a unique position because it combines screening, diagnosis, biopsy, and therapy in one procedure. A screening case can convert into an intervention when a polyp is identified, creating incremental utilization of snares, clips, retrieval devices, injection needles, pathology collection products, electrosurgical tools, and advanced imaging. The lowering of the screening starting age to 45 expanded the addressable population and supports a durable procedure base through the forecast period.

A second driver is the continued migration of appropriate procedures from hospital outpatient departments toward ambulatory surgery centers. Outpatient gastroenterology already has a mature ASC footprint, but site-of-care economics continue to encourage further migration. For procedures covered in both settings, Medicare ASC payment rates are generally materially lower than hospital outpatient rates, giving payers a strong economic incentive to direct suitable patients toward lower-cost facilities. Patients can also benefit from lower cost sharing, convenient scheduling, and shorter non-procedure time. For device suppliers, this creates a different customer profile: physician owners and ASC operators tend to place greater emphasis on capital efficiency, service responsiveness, disposable cost, room turnover, and equipment standardization.

A third driver is expansion of the U.S. ASC base itself. Medicare-certified ASCs increased by more than 2% annually on average between 2019 and 2024, reaching more than 6,400 facilities. Gastroenterology remains one of the largest specialty categories within this infrastructure. Each new GI-capable facility can create demand for endoscopy processors, colonoscopes, gastroscopes, electrosurgical equipment, insufflation and irrigation systems, automated reprocessors, drying and storage equipment, procedure accessories, recovery monitoring, cleaning consumables, and digital documentation systems. This makes facility formation an important leading indicator for device demand.

The fourth driver is the growing therapeutic intensity of outpatient endoscopy. Gastroenterologists are moving beyond diagnostic visualization toward more complex interventions such as large-polyp management, endoscopic mucosal resection, selected endoscopic submucosal dissection, endoscopic suturing, defect closure, advanced hemostasis, luminal stenting, EUS-guided interventions, and third-space procedures. Not every advanced case will migrate to a freestanding ASC, but the overall direction increases device value per procedure. A complex outpatient case can require substantially more disposable technology than a routine diagnostic examination.

A fifth driver is the adoption of AI-assisted lesion detection and enhanced imaging. Quality in colonoscopy is increasingly tied to reliable identification of adenomas and other clinically significant lesions. Computer-aided detection systems provide real-time visual alerts while advanced optical technologies enhance mucosal and vascular contrast. The business implication is significant: imaging competition is shifting from pixel resolution alone toward a combined proposition incorporating AI, lesion characterization, measurement, documentation, and workflow integration. Platforms that can demonstrate measurable quality improvements without slowing procedure throughput are particularly attractive to high-volume outpatient facilities.

A sixth driver is the replacement cycle for reusable endoscopy infrastructure. A large installed base of colonoscopes, gastroscopes, processors, light sources, electrosurgical generators, reprocessors, and storage equipment requires continuous replacement and servicing. Heavy outpatient utilization accelerates wear because high-volume centers may turn individual scopes over multiple times during a clinical day. Purchasing decisions therefore involve not just acquisition price but repair history, preventive maintenance, backup inventory, reprocessing capacity, turnaround time, service agreements, and expected usable life.

A seventh driver is infection prevention and reprocessing economics. Flexible endoscopes are complex reusable devices, and compliant reprocessing requires trained staff, cleaning chemistry, leak testing, automated high-level disinfection, drying, storage, documentation, water management, quality assurance, and workflow discipline. This creates demand for automated endoscope reprocessors, drying cabinets, tracking systems, cleaning verification tools, transport products, detergents, valves, brushes, and other infection-prevention consumables. It also provides a commercial opening for single-use scopes in situations where sterility, immediate availability, procedure location, or reprocessing capacity outweigh the per-procedure economics of reusable equipment.

Finally, reimbursement policy remains an important accelerator and constraint. For 2026, Medicare increased qualifying ASC payment rates by 2.6%, maintaining a payment framework linked to hospital outpatient reimbursement but with substantially lower ASC base payment economics. This reinforces the need for devices to fit outpatient cost structures. Manufacturers able to demonstrate shorter procedure time, reduced accessory use, lower repair burden, fewer repeat procedures, reduced reprocessing complexity, or better clinical quality can translate technical differentiation into an economic argument that ASC owners can evaluate directly.

 

Innovation in Focus: How Manufacturers Are Raising the Bar?

Innovation in outpatient gastroenterology is moving from stand-alone hardware toward integrated procedure ecosystems. A modern GI platform increasingly combines endoscope optics, image processors, multiple image-enhancement modes, AI-assisted detection, electrosurgical compatibility, water irrigation, insufflation, accessories, procedure documentation, and equipment-service data. The strategic value of integration is particularly high in ASCs because workflow interruptions have a direct impact on daily case throughput and facility economics.

Artificial intelligence is one of the most consequential technology cycles. AI-assisted colonoscopy systems can analyze live endoscopic video and highlight regions consistent with colorectal lesions. FDA clearances across GI Genius, CADDIE, CAD EYE and other systems have moved computer-aided detection from experimental use toward a genuine procurement category. During the forecast period, AI competition is expected to evolve from basic polyp alerts toward lesion characterization, quality measurement, bowel-preparation assessment, automated documentation, procedure analytics, and integration into enterprise endoscopy platforms.

Image-enhanced endoscopy is advancing in parallel. Narrow-band and multi-light imaging, linked color imaging, blue-light imaging, texture and color enhancement, high-definition CMOS sensors, 4K processing, improved dynamic range, and digital lesion measurement are designed to make subtle abnormalities easier to identify and characterize. For outpatient buyers, the important question is whether improved visualization produces better clinical performance without requiring disruptive changes in procedure technique.

Therapeutic endoscopy represents another major innovation frontier. Newer clips, suturing systems, tissue-resection platforms, hemostatic technologies, electrosurgical knives, graspers, retrieval systems, dilation devices, guidewires, stents, and EUS-guided accessories are expanding the number of conditions that can be treated endoscopically. This matters economically because shifting a patient from surgery or an inpatient pathway to endoscopic treatment can reduce recovery requirements and create a stronger clinical rationale for investment in advanced endoscopy programs.

Single-use endoscopy is also becoming strategically relevant. Disposable gastroscopes, colonoscopes and duodenoscopes are not expected to replace reusable endoscopy across all high-volume outpatient procedures during the forecast period. Their economic profile remains procedure- and facility-dependent. However, they can provide value for backup capacity, infection-sensitive cases, satellite locations, low-volume programs, after-hours availability, and procedures in which reprocessing complexity creates disproportionate operational cost. Improvements in image quality and working-channel performance are gradually narrowing the historical performance gap.

Endoscope reprocessing is becoming more automated and traceable. Facilities are increasingly evaluating reprocessing as part of the device platform rather than as a separate back-room function. Automated high-level disinfection, drying systems, electronic scope tracking, cycle documentation, leak testing, cleaning verification, water-quality management, and workflow analytics can reduce variability and provide auditable process control. For large GI centers, preventing a reprocessing bottleneck can be as important as adding another procedure room.

Manufacturers are also improving outpatient economics through scope durability, modular processors, backward compatibility, reusable-to-single-use portfolio options, digital service diagnostics, and more flexible capital contracting. Because independent ASCs generally have less capital flexibility than large health systems, financing structures, service guarantees, utilization-based agreements, and bundled disposable contracts can materially affect vendor selection.

 

Segmentation Insights

The U.S. Outpatient Gastroenterology Devices Market is segmented on the basis of product category, application, end user, technology type, and region.

 

By Product Category

• Endoscopes and visualization systems represent the largest product category and are estimated to account for approximately 38% of the 2025 market. This segment includes colonoscopes, gastroscopes, duodenoscopes, enteroscopes, EUS scopes, video processors, light sources, monitors, camera and imaging components, insufflation systems, irrigation technologies, and related capital equipment. The segment benefits from a substantial replacement cycle and continuous competition around image quality, ergonomics, scope handling, advanced visualization, interoperability, and AI compatibility. Capital purchasing is increasingly platform-based, giving suppliers with broad scope families and strong service organizations an advantage.
• Endotherapy and therapeutic accessories form one of the most attractive recurring-revenue categories. Products include biopsy forceps, polypectomy snares, injection needles, guidewires, retrieval baskets and nets, clips, tissue-closure devices, dilation balloons, electrosurgical accessories, hemostasis devices, foreign-body retrieval tools, cannulation products, endoscopic suturing technologies, and gastrointestinal stents. Growth is being driven by rising procedure intensity rather than diagnostic volume alone. Large-polyp treatment, advanced closure, bleeding management and EUS-guided intervention can materially increase disposable revenue per case.
• Endoscope reprocessing and infection-prevention devices include automated endoscope reprocessors, drying and storage systems, transport containers, leak testers, cleaning verification technologies, brushes, detergents, connectors, valves, irrigation products, tracking software, and related infection-control equipment. This category is strategically important because the operational cost of reusable endoscopy extends well beyond scope acquisition. High-throughput outpatient centers require reliable reprocessing capacity to prevent procedure-room downtime.
• GI diagnostic, capsule and functional testing devices include capsule endoscopy systems, esophageal and anorectal manometry equipment, impedance-pH monitoring systems, breath-testing equipment where device based, wireless motility technologies, and specialized outpatient diagnostic platforms. This segment is smaller by value than conventional endoscopy but benefits from movement toward non-surgical, office-based evaluation and from demand for improved diagnosis of small-bowel disease, reflux, swallowing disorders, constipation, and pelvic-floor dysfunction.
• AI-enabled and digital endoscopy technologies represent the fastest-growing product layer. The segment includes computer-aided detection, lesion characterization, image measurement, procedure analytics, endoscopy workflow software, quality-monitoring applications, and software integrated with endoscopic processors. Revenue remains smaller than traditional hardware and disposables, but AI increasingly influences the selection of the underlying imaging platform and may become an important source of recurring software revenue.

 

By Application

• Colorectal cancer screening, surveillance and polyp management constitute the largest application segment. The addressable procedure base includes screening colonoscopy, surveillance of patients with prior polyps, diagnostic colonoscopy, biopsy, polypectomy, mucosal resection, bleeding management and lesion closure. The clinical objective is increasingly shifting from completing the examination to maximizing high-quality lesion recognition and complete removal. This supports demand for advanced imaging, AI detection, snares, clips, retrieval devices, injection technologies and electrosurgical products.
• Upper gastrointestinal diagnosis and therapy include evaluation and treatment of reflux-related disease, dysphagia, Barrett’s esophagus, ulcers, gastrointestinal bleeding, strictures, gastric and esophageal lesions, and other upper-GI disorders. Gastroscopes remain a foundational device category, while disposable utilization is supported by biopsy, dilation, hemostasis and retrieval procedures. New ultra-slim and therapeutic gastroscopes are broadening the range of outpatient interventions that can be performed through upper endoscopy.
• Pancreatobiliary and advanced EUS procedures represent a high-value application area even though many complex cases remain hospital based. EUS-guided biopsy, pancreatic and biliary evaluation, selected drainage procedures, ERCP accessories, guidewires, cannulation products and stents generate substantial device revenue per case. As physician experience improves and technologies become more standardized, selected lower-risk procedures are expected to move further into outpatient programs capable of managing the necessary anesthesia and emergency protocols.
• Inflammatory bowel disease, lower-GI disorders and gastrointestinal bleeding create recurring diagnostic and surveillance requirements. Patients with chronic disease may undergo repeated colonoscopy and tissue sampling, while bleeding episodes require injection, clipping, thermal or other hemostatic technologies. Demand is particularly valuable to manufacturers because chronic patient populations create longitudinal procedure utilization rather than one-time intervention.
• Motility disorders, metabolic endoscopy and other outpatient GI applications include capsule diagnostics, reflux testing, esophageal and anorectal manometry, endoscopic obesity therapy, selected third-space procedures and other emerging indications. This segment has a smaller base but offers strong innovation potential because it expands gastroenterology beyond conventional diagnostic endoscopy into disease management traditionally addressed through surgery, pharmacotherapy, or less precise diagnostic pathways.

 

By End User

• Gastroenterology-focused ambulatory surgery centers are the most strategically important end-user segment. More than 1,200 single-specialty GI ASCs billed fee-for-service Medicare in 2024, with additional gastroenterology capacity located in multispecialty centers. These facilities typically perform high volumes of colonoscopy and upper endoscopy and are therefore intensive users of scopes, imaging platforms, snares, biopsy devices, clips, reprocessing systems and infection-prevention consumables. Physician ownership also means purchasing decisions are closely connected to procedure economics and operational efficiency.
• Hospital outpatient departments remain critical because they treat a broader risk mix and perform many higher-complexity GI procedures that may not be suitable for freestanding ASCs. HOPDs are especially important for EUS, ERCP, advanced resection, medically complex patients and procedures requiring immediate access to inpatient resources. Their procurement environment favors integrated platforms, enterprise contracting, compatibility across multiple specialties, advanced clinical functionality and evidence-based value analysis.
• Office-based gastroenterology clinics and physician-owned endoscopy centers are important for diagnostic testing, motility, capsule endoscopy, selected unsedated examinations, follow-up and lower-complexity procedures. These facilities favor compact systems, simple installation, predictable per-test economics, cloud connectivity and reduced technical staffing requirements.
• Academic medical center outpatient programs and specialty referral centers represent a smaller volume segment but exert disproportionate influence on technology adoption. Advanced endoscopic resection, EUS-guided intervention, third-space endoscopy, clinical trials and early adoption of new imaging or AI platforms frequently begin in these institutions before moving to high-volume community practice.
• Specialty diagnostic and motility centers account for a focused but expanding end-user base for capsule systems, manometry, reflux monitoring and other functional GI technologies. Their purchasing priorities center on diagnostic accuracy, software usability, patient throughput, consumable cost and the ability to integrate results into gastroenterology practice workflows.

 

By Technology Type

• Reusable flexible endoscopy systems remain the backbone of the market. High-volume outpatient colonoscopy and upper endoscopy generally favor reusable scopes because capital costs can be distributed across substantial procedure volumes. Competition centers on image quality, durability, insertion characteristics, ergonomics, maintenance, repair frequency, reprocessing requirements and processor compatibility.
• Single-use and disposable endoscopy technologies are the fastest-changing alternative to traditional reusable equipment. Disposable gastroscopes, colonoscopes and duodenoscopes eliminate reprocessing for the individual device and provide predictable scope availability. Adoption is expected to remain selective rather than universal, but outpatient facilities may increasingly use single-use devices to supplement reusable fleets or manage specific clinical scenarios.
• High-definition, 4K and image-enhanced endoscopy are becoming standard components of premium outpatient systems. Technologies that enhance mucosal pattern, vascular detail, color contrast or depth perception can support earlier lesion recognition and more confident therapeutic decision-making. The value proposition is strongest when advanced visualization can be deployed through existing physician workflows.
• AI-assisted and software-enabled endoscopy is expected to record the strongest technology growth through 2035. Computer-aided detection has established an initial commercial use case, but the longer-term opportunity includes characterization, measurement, quality scoring, automated reporting and workflow analytics. Interoperability across multiple endoscope brands will be a meaningful competitive factor for stand-alone AI vendors.
• Connected reprocessing, traceability and workflow technologies represent an increasingly important operational layer. Automated tracking from bedside pre-cleaning through disinfection, drying, storage and next use can provide facilities with improved process documentation and equipment utilization data. Outpatient centers with high procedure volumes are likely to invest more aggressively in technologies that reduce manual workflow variability and prevent reprocessing capacity from constraining daily throughput.

 

Regional Insights: Where the Market Is Growing Fastest

The U.S. Outpatient Gastroenterology Devices Market is geographically segmented into the South, West, Northeast and Midwest. Regional performance differs substantially according to population growth, age structure, colorectal cancer burden, gastroenterologist density, concentration of ASCs, hospital outpatient infrastructure, certificate-of-need regulation, commercial payer penetration, Medicare enrollment, physician ownership patterns, and willingness to adopt premium endoscopic technologies.

South

The South is estimated to represent the largest regional market at approximately USD 2.64 billion in 2025 and is projected to reach around USD 6.10 billion by 2035, reflecting an approximately 8.74% CAGR. The region includes Texas, Florida, Georgia, North Carolina, South Carolina, Virginia, Maryland, Tennessee, Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma, West Virginia and surrounding Southern markets.

Its leadership is driven by the combination of large population bases, rapid Sun Belt growth, substantial Medicare populations, chronic digestive disease demand, expanding physician-owned outpatient infrastructure, and comparatively favorable conditions for ASC formation in several states. The region is also particularly important for manufacturers because it contains both very large metropolitan procedure markets and underserved areas where regional GI groups are expanding satellite endoscopy capacity.

Texas and Florida are the two largest commercial opportunities. Texas is estimated to record approximately 12,700 new colorectal cancer cases in 2025, while Florida is expected to record about 12,330. Houston, Dallas-Fort Worth, Austin, San Antonio, Miami, Tampa, Orlando and South Florida contain large GI practice networks, hospital outpatient departments and ASC clusters capable of supporting premium capital equipment as well as high recurring accessory volumes. Florida’s older population creates especially strong demand for colorectal surveillance, polypectomy, upper-GI evaluation and therapeutic endoscopy.

Georgia and North Carolina are emerging as particularly attractive ASC markets. Georgia is expected to record roughly 5,160 new colorectal cancer cases in 2025 and has one of the highest concentrations of ASCs relative to its Medicare population. Regulatory changes in Georgia and North Carolina have also reduced certain certificate-of-need constraints for new outpatient surgical capacity, improving the long-term development environment. These states therefore offer manufacturers an opportunity to win new-room installations rather than compete solely for replacement business.

Maryland is structurally distinct. It recorded the highest concentration of ASCs relative to Medicare Part B beneficiaries in 2024, at approximately 36 centers per 100,000 beneficiaries. Its all-payer hospital payment environment has historically provided a stronger incentive to move suitable procedures away from hospital campuses. This creates a dense outpatient purchasing environment despite Maryland’s smaller population.

Tennessee, Virginia and South Carolina offer strong growth through integrated GI practices, health-system expansion and metropolitan population inflows. Alabama, Mississippi, Louisiana, Arkansas, Kentucky, Oklahoma and West Virginia carry substantial digestive disease and cancer burdens but have greater rural-access constraints. In these markets, device companies require different commercial models: advanced capital systems are concentrated in referral centers, while portable diagnostics, capsule technologies, standardized endotherapy portfolios and reliable service coverage can be more important across smaller communities.

By 2035, the South should remain the largest regional revenue pool. The highest-value opportunities will be tied to ASC construction and consolidation, installed-base replacement, colorectal screening, AI-enabled colonoscopy, advanced polypectomy and closure, reprocessing automation, and greater penetration of therapeutic endoscopy outside traditional tertiary hospitals.

West

The West is estimated at approximately USD 1.70 billion in 2025 and is forecast to reach around USD 4.03 billion by 2035, representing the fastest regional CAGR of approximately 9.01%. The region includes California, Washington, Arizona, Colorado, Oregon, Nevada, Utah, New Mexico, Idaho, Montana, Wyoming, Alaska and Hawaii.

California is the region’s largest individual market and one of the most important outpatient gastroenterology device markets nationally. Approximately 16,040 new colorectal cancer cases are expected in California in 2025, the highest state-level total in the country. The state combines large procedure volumes with major academic medical centers, sophisticated integrated delivery networks, specialist GI groups and an innovation-oriented technology market. Advanced imaging, AI-supported colonoscopy, EUS, endoscopic resection, digital workflow systems and premium therapeutic devices often gain early clinical exposure in California before wider commercial adoption.

Arizona represents one of the strongest outpatient growth opportunities. Its expanding and aging population supports screening, surveillance and upper-GI procedures, while the state recorded approximately 18 ASCs per 100,000 Medicare Part B beneficiaries in 2024, among the highest concentrations nationally. Phoenix and other population centers are therefore attractive for both new facility installations and recurring endoscopy consumables.

Washington, Colorado, Utah and Nevada combine population growth with sophisticated provider networks and strong adoption of digital health and advanced procedure technology. Washington is expected to record approximately 3,240 new colorectal cancer cases in 2025, while Arizona is expected to record about 3,220. Colorado and Utah have younger demographic profiles than some Eastern states, but rapid population expansion and concentrated metropolitan GI networks create strong capital-equipment opportunities.

Oregon, Idaho, Montana, Wyoming, Alaska, Hawaii and New Mexico are smaller state markets but are strategically important for portable, compact or flexible outpatient technologies. Alaska recorded approximately 17 ASCs per 100,000 Medicare beneficiaries in 2024 despite its small population, illustrating that absolute market size and ASC density can differ significantly. Rural geography in several Western states also raises the value of satellite sites, telehealth-enabled diagnostics and equipment models that reduce dependence on centralized tertiary facilities.

The West is expected to gain national market share through 2035 because its providers are relatively receptive to image-enhanced endoscopy, AI, advanced therapeutic platforms and new care-delivery models. Vendors that can demonstrate measurable workflow gains and integrate new software with existing endoscopy hardware should find particularly favorable adoption conditions in this region.

Northeast

The Northeast is estimated to account for approximately USD 1.73 billion in 2025 and is projected to reach around USD 3.63 billion by 2035, at an estimated CAGR of 7.69%. The region includes New York, Pennsylvania, New Jersey, Massachusetts, Connecticut, Maine, Vermont, New Hampshire, Rhode Island and Delaware.

The Northeast is a premium-value rather than high-ASC-density market. It has an exceptional concentration of academic medical centers, tertiary referral institutions, subspecialty gastroenterologists, inflammatory bowel disease programs, advanced endoscopy centers and clinical research infrastructure. Complex outpatient procedures, EUS, advanced polypectomy, endoscopic resection and early technology evaluations are therefore disproportionately important.

New York is the region’s largest state market, with approximately 8,920 new colorectal cancer cases expected in 2025. New York City and the surrounding metropolitan area support high-volume hospital outpatient and independent GI networks, while upstate markets provide a broad community endoscopy base. Pennsylvania follows with approximately 6,500 projected cases, supported by major programs in Philadelphia, Pittsburgh and regional health systems.

New Jersey is expected to record about 4,430 new colorectal cancer cases in 2025 and has a commercially attractive combination of population density, high insurance coverage and strong ambulatory care penetration. Massachusetts, with approximately 2,770 expected cases, is smaller by population but highly influential because Boston-based academic systems regularly participate in evaluations of advanced imaging, AI, interventional endoscopy and new therapeutic devices.

Connecticut, Rhode Island, New Hampshire and Maine support smaller but comparatively high-value outpatient procedure markets. Vermont presents a different environment: its ASC concentration is among the lowest nationally, illustrating how certificate-of-need regulation, population density and hospital-centered care structures can limit freestanding facility growth even when clinical demand exists.

The Northeast’s CAGR is expected to trail the West and South because population growth is slower and much of the endoscopy infrastructure is mature. However, revenue per advanced procedure and adoption of premium devices should remain strong. Manufacturers are likely to win in this region through evidence generation, clinical education, key-opinion-leader engagement, advanced-service support and clear integration with complex hospital and academic procurement systems.

Midwest

The Midwest is estimated at approximately USD 1.58 billion in 2025 and is forecast to reach around USD 3.46 billion by 2035, representing an estimated CAGR of 8.15%. The region includes Illinois, Ohio, Michigan, Minnesota, Indiana, Wisconsin, Missouri, Iowa, Kansas, Nebraska, North Dakota and South Dakota.

Illinois and Ohio represent the two largest state-level opportunities. Illinois is expected to record approximately 6,110 new colorectal cancer cases in 2025, while Ohio is expected to record around 5,760. Chicago, Cleveland, Columbus and Cincinnati support large academic and community gastroenterology networks with significant colonoscopy, upper endoscopy and advanced endotherapy capacity.

Michigan is expected to record approximately 4,710 new colorectal cancer cases in 2025 and has a large integrated health-system footprint. Indiana, with around 3,410 projected cases, provides a strong combination of metropolitan and community ASC demand. Wisconsin and Minnesota are expected to record approximately 2,630 and 2,600 new colorectal cancer cases respectively. Minnesota is particularly important from a medtech perspective because its medical-device ecosystem and sophisticated provider organizations can facilitate evaluation of new GI technologies.

Missouri, Iowa, Kansas and Nebraska provide stable procedure demand and a strong base of community gastroenterology. The Dakotas represent smaller markets with greater geographic dispersion. In rural Midwestern areas, patients frequently travel to regional referral centers for endoscopy, making equipment reliability and distributor or manufacturer service coverage important purchasing considerations.

The Midwest is unlikely to exhibit the same population-driven expansion as the Sun Belt, but it should remain a durable market for endoscope replacement, colorectal screening, therapeutic accessories, reprocessing infrastructure, motility diagnostics and AI-assisted colonoscopy. Procurement tends to place strong weight on clinical reliability, service response, standardized contracting and demonstrable cost per case. Vendors able to combine premium technology with disciplined lifecycle economics should perform well across major Midwestern health systems and independent GI networks.

 

Key Market Players

The U.S. Outpatient Gastroenterology Devices Competitive Landscape is concentrated at the imaging-platform level but considerably more fragmented across endotherapy, diagnostics, AI, single-use endoscopy and specialty procedure technologies. Olympus, FUJIFILM and PENTAX Medical maintain strong positions in reusable flexible endoscopy and visualization, while Boston Scientific, Cook Medical, Micro-Tech, Merit Medical, CONMED, ERBE and other companies compete across therapeutic accessories. Medtronic combines capsule endoscopy and AI-supported colonoscopy capabilities, while Ambu is expanding the competitive relevance of single-use GI scopes.

Some of the key players operating in the U.S. outpatient gastroenterology devices industry include:

Olympus Corporation
Boston Scientific Corporation
Medtronic plc
FUJIFILM Healthcare Americas Corporation
PENTAX Medical / HOYA Corporation
STERIS plc
Ambu A/S
Cook Medical
CONMED Corporation
KARL STORZ SE & Co. KG
ERBE Elektromedizin GmbH / ERBE USA
Micro-Tech Endoscopy USA
Merit Medical Systems, Inc.
Ovesco Endoscopy USA
Creo Medical Group plc
Laborie Medical Technologies
Diversatek Healthcare
CapsoVision, Inc.
AnX Robotica
EvoEndo, Inc.
EndoGastric Solutions, Inc.
Lumendi Ltd.
Cosmo Pharmaceuticals / Cosmo Intelligent Medical Devices

Competition is increasingly organized around clinical ecosystems rather than individual SKUs. A manufacturer that owns the endoscopy processor has an opportunity to influence scope selection, AI functionality, service contracts and imaging upgrades. A therapeutic-device supplier can increase account penetration by building procedure-specific portfolios for polypectomy, bleeding, biliary intervention or tissue closure. Reprocessing suppliers influence lifecycle economics and infection-control performance, while AI vendors can become an important software layer across otherwise competing hardware platforms.

For outpatient customers, competitive differentiation will increasingly depend on five variables: clinical performance, procedure efficiency, capital and lifecycle economics, service reliability, and portfolio integration. Physician-owned centers are particularly sensitive to downtime because a failed processor, unavailable scope or reprocessing bottleneck directly affects daily case revenue. Manufacturers with responsive field service, replacement equipment, preventive maintenance programs and predictable accessory supply therefore have an advantage that is not captured by device specifications alone.

Consolidation will remain an important competitive strategy. Large medtech companies are likely to continue acquiring differentiated GI therapeutic, AI and diagnostic technologies in order to increase the amount of revenue captured per procedure. At the same time, specialist companies can remain competitive when they address a narrow but expensive clinical problem, particularly in advanced closure, resection, motility, capsule diagnostics, single-use endoscopy and procedure-enabling software.

 

Recent Developments

Recent developments in the U.S. Outpatient Gastroenterology Devices Market demonstrate that competition is shifting simultaneously across imaging, artificial intelligence, single-use endoscopy and advanced therapeutic products.

In 2026, the FDA cleared updated GI Genius Module 300 and ColonPRO configurations, continuing the expansion of AI-assisted lesion-detection technology in colonoscopy. AI is transitioning from an optional add-on toward a potentially important component of quality-oriented outpatient colonoscopy programs, particularly for high-volume centers that want more consistent lesion recognition across physicians and procedure sessions.

Fujifilm continued a broad U.S. endoscopy technology refresh. The company commercialized next-generation 800-Series therapeutic gastroscopes in 2025 and subsequently launched the ELUXEO 8000 Endoscopic Imaging System, combining advanced image processing with multiple image-enhancement modes. Earlier, in 2024, Fujifilm obtained U.S. clearance for CAD EYE, an AI-supported colonic lesion detection technology, and SCALE EYE, which provides virtual measurement support for colorectal lesions. These developments illustrate the market’s shift toward imaging platforms that combine visualization, detection and procedural decision support.

Olympus received U.S. clearance in May 2025 for new colonovideoscope and gastrointestinal videoscope models in its EZ1500 family, reinforcing continued product iteration within the large reusable endoscopy installed base. Olympus has also strengthened its therapeutic GI portfolio through the acquisition of Taewoong Medical, a specialist in gastrointestinal metallic stents, expanding its ability to compete beyond visualization and into higher-value endotherapy.

Single-use endoscopy also advanced. The FDA cleared Ambu’s aScope Gastro Large with aBox 2 in April 2024 and its second-generation single-use duodenoscope system during the same period. These products increase competition around the traditional reusable-scope model and provide outpatient centers with additional options for backup inventory, infection-sensitive procedures and locations where reprocessing infrastructure is constrained.

Regulatory and reimbursement conditions continue to support outpatient migration. Medicare’s 2026 ASC payment update increased qualifying ASC rates by 2.6%, while the broader ASC covered-procedure framework continued to expand. The commercial effect is not that every newly eligible procedure will immediately move from a hospital, but that providers have a widening regulatory pathway to evaluate outpatient delivery when patient risk, anesthesia, staffing and emergency-support requirements can be managed safely.

Mergers and portfolio expansion are likely to remain important through 2035. The acquisition of specialist endotherapy and obesity-intervention technologies by larger medtech companies demonstrates the value of controlling a broader share of the GI procedure. Future transactions are likely to focus on AI, advanced endoscopic therapy, single-use technology, tissue closure, EUS, motility diagnostics and workflow software.

 

Conclusion

The U.S. Outpatient Gastroenterology Devices Market Size & Share is positioned to increase from approximately USD 7.65 billion in 2025 to USD 17.22 billion by 2035, representing a CAGR of 8.45% during 2026–2035. The historical market expanded from an estimated USD 5.34 billion in 2021 to USD 7.03 billion in 2024 as elective endoscopy normalized, colorectal screening recovered, ASC capacity expanded and manufacturers introduced higher-value imaging and therapeutic technologies.

The market’s long-term growth case is structurally stronger than a simple procedure-volume forecast. Gastroenterology already has one of the largest dedicated ASC footprints in the United States, and colonoscopy and upper-GI endoscopy account for a substantial share of Medicare ASC activity. At the same time, the amount of device value consumed during each procedure is rising through AI, image enhancement, advanced resection, hemostasis, closure, EUS, stenting and digital workflow technologies.

The highest-value product opportunities through 2035 are expected in advanced endoscopy and visualization platforms, AI-assisted colonoscopy, endotherapy disposables, automated reprocessing, infection-prevention technologies, single-use scopes for selected workflows, EUS accessories, tissue closure and advanced polyp-management devices. Mature categories such as conventional reusable colonoscopes and biopsy accessories will remain essential, but competitive growth will increasingly depend on reducing total procedure cost or enabling a higher level of care in an outpatient environment.

Regional opportunity will remain led by the South, supported by Texas, Florida, Georgia, North Carolina and a rapidly expanding outpatient infrastructure. The West should generate the fastest growth due to technology adoption, population expansion and strong ASC penetration in states such as Arizona. The Northeast will remain a premium market for advanced and evidence-driven technologies despite slower facility expansion, while the Midwest will provide durable demand supported by large community GI networks and replacement-driven purchasing.

For manufacturers, investors, distributors and outpatient providers evaluating this market, the central strategic issue is not simply how many colonoscopies will be performed. The more important questions are where procedures will be performed, how much technology value can be captured per case, which devices materially improve throughput or quality, and how procurement shifts as physicians assume greater responsibility for facility economics.

The companies best positioned to lead the U.S. outpatient gastroenterology devices industry through 2035 will be those capable of combining differentiated clinical technology with measurable workflow improvement, strong service infrastructure, disciplined cost-per-case economics, reimbursement awareness and evidence that matters to both physicians and outpatient facility owners.

 

TABLE OF CONTENT

1. U.S. Outpatient Gastroenterology Devices Market: Market Introduction & Context

1.1. Market Definition
1.2. Scope of the Study
1.3. Research Methodology
1.3.1. Primary Data Collection
1.3.2. Secondary Data Sourcing
1.3.3. External Industry Collaborations
1.3.4. In-House Research Databases
1.3.5. Analytical Frameworks & Forecasting Models
1.3.6. Data Validation and Final Report Publishing
1.4. Key Assumptions
1.5. Market Ecosystem Overview
1.6. Stakeholder Analysis
1.6.1. Gastroenterology Device Manufacturers
1.6.2. Endoscopy Component and Contract Manufacturing Suppliers
1.6.3. Ambulatory Surgery Centers
1.6.4. Hospital Outpatient Departments
1.6.5. Gastroenterology Practices and Physician-Owned Endoscopy Centers
1.6.6. Academic and Advanced Endoscopy Centers
1.6.7. Group Purchasing Organizations and Specialty Distributors
1.6.8. Payers, Regulators, Accreditation Bodies, and Clinical Decision-Makers

What this section provides: This section defines the U.S. outpatient gastroenterology devices market boundary, study scope, methodology, assumptions, care settings, and stakeholder ecosystem so clients understand how market size and forecast estimates are constructed and validated.

2. U.S. Outpatient Gastroenterology Devices Market: Executive Summary

2.1. Key Insights & Market Snapshot
2.2. Analyst Viewpoint
2.3. Market Attractiveness Index
2.4. Historical Market Summary, 2021–2024
2.5. Base Year Market Positioning, 2025
2.6. Forecast Outlook, 2026–2035
2.7. Market Size, 2021–2035 (US$ Billion)
2.8. CAGR Analysis, 2026–2035
2.9. Leading Segment Analysis
2.10. Fastest-Growing Segment Analysis
2.11. Leading Regional Market Analysis
2.12. Fastest-Growing Regional Market Analysis
2.13. High-Growth Opportunity Areas
2.14. Key Investment Themes

What this section provides: This section gives decision-makers a concise view of the market’s USD 7.65 billion 2025 position, expected USD 17.22 billion 2035 opportunity, 8.45% forecast CAGR, leading segments, regional opportunities, competitive intensity, and strategic growth pockets.

3. U.S. Outpatient Gastroenterology Devices Market: Market Dynamics & Outlook

3.1. Drivers and Their Impact Analysis
3.1.1. Rising Colorectal Cancer Screening and Surveillance Demand
3.1.2. Expansion of Gastroenterology-Focused Ambulatory Surgery Centers
3.1.3. Migration of GI Procedures from Hospitals to Outpatient Settings
3.1.4. Increasing Therapeutic Intensity of Outpatient Endoscopy
3.1.5. Growing Adoption of AI-Assisted Colonoscopy
3.1.6. Replacement Cycle for Endoscopy Towers and Reusable Scopes
3.1.7. Rising Demand for Single-Use Endoscopy Technologies
3.1.8. Increasing Focus on Infection Prevention and Endoscope Reprocessing
3.1.9. Aging U.S. Population and Rising Digestive Disease Burden
3.1.10. Expansion of Physician-Owned Gastroenterology Platforms
3.2. Restraints and Their Impact Analysis
3.2.1. High Capital Cost of Advanced Endoscopy Systems
3.2.2. Reimbursement Pressure in Ambulatory Surgery Centers
3.2.3. Endoscope Repair and Maintenance Costs
3.2.4. Reprocessing Complexity and Infection-Control Compliance
3.2.5. Gastroenterologist and Endoscopy Nursing Workforce Constraints
3.2.6. Price Sensitivity of Independent Outpatient Facilities
3.2.7. Regulatory and Product Recall Risks
3.3. Opportunities and Their Impact Analysis
3.3.1. AI-Assisted Polyp Detection and Characterization
3.3.2. Advanced Polypectomy and Endoscopic Resection
3.3.3. Single-Use Gastroscopes, Colonoscopes, and Duodenoscopes
3.3.4. EUS-Guided Outpatient Interventions
3.3.5. Endoscopic Suturing, Closure, and Hemostasis Technologies
3.3.6. Automated Endoscope Reprocessing and Digital Traceability
3.3.7. Capsule Endoscopy and Functional GI Diagnostics
3.3.8. Bariatric and Metabolic Endoscopy
3.3.9. Satellite and Rural Outpatient Endoscopy Expansion
3.4. Challenges and Their Impact Analysis
3.4.1. Balancing Premium Technology with ASC Cost-per-Case Economics
3.4.2. Reusable Versus Single-Use Endoscope Economics
3.4.3. Integration of AI with Legacy Endoscopy Platforms
3.4.4. Procedure Migration and Patient Selection Constraints
3.4.5. Variability in State-Level ASC Regulation
3.5. Patent & Innovation Analysis, 2021–2025
3.6. Outpatient GI Clinical Workflow Economics Analysis
3.7. ASC Capital Procurement Behavior Analysis
3.8. Endoscopy Installed-Base Replacement Cycle Analysis
3.9. Procedure Volume–Device Consumption Correlation Analysis

What this section provides: This section explains the clinical, demographic, reimbursement, technological, operational, and economic forces influencing outpatient GI device demand and helps clients identify growth catalysts, commercial barriers, and execution risks.

4. U.S. Outpatient Gastroenterology Devices Market: Market Environment & Industry Analysis

4.1. PESTEL Analysis
4.1.1. Political
4.1.2. Economic
4.1.3. Social
4.1.4. Technological
4.1.5. Environmental
4.1.6. Legal
4.2. Porter’s Five Forces Analysis
4.2.1. Threat of New Entrants
4.2.2. Bargaining Power of Outpatient Facility Buyers
4.2.3. Bargaining Power of Suppliers
4.2.4. Substitution Risk
4.2.5. Competitive Rivalry
4.3. Pricing Trend Analysis by Region, 2025–2035
4.4. Value Chain & Supply Chain Analysis
4.5. U.S. Endoscopy Installed-Base Analysis
4.6. Impact of Digitalization and Connected Endoscopy
4.7. Artificial Intelligence Adoption Landscape
4.8. Application & Innovation Landscape
4.9. FDA Regulatory Framework Analysis
4.10. FDA 510(k), De Novo, and PMA Pathway Relevance
4.11. CMS Reimbursement and ASC Coverage Landscape
4.12. Medicare ASC Versus HOPD Payment Economics
4.13. Commercial Payer Site-of-Care Policies
4.14. Infection Prevention and Endoscope Reprocessing Standards
4.15. Import/Export Restrictions & Tariff Impact
4.16. Government Colorectal Cancer Screening Initiatives
4.17. Impact of Escalating Geopolitical Tensions
4.18. Sustainability Impact of Reusable Versus Single-Use Devices
4.19. Outpatient Value Analysis Committee Decision Framework

What this section provides: This section gives clients a comprehensive view of regulation, reimbursement, pricing, AI adoption, infection prevention, supply-chain conditions, environmental considerations, technology development, and purchasing dynamics influencing the U.S. outpatient GI device industry.

5. U.S. Outpatient Gastroenterology Devices Market – By Product Category

5.1. Overview
5.1.1. Segment Share Analysis, By Product Category, 2025 & 2035 (%)
5.1.2. Endoscopes and Visualization Systems
5.1.2.1. Colonoscopes
5.1.2.2. Gastroscopes
5.1.2.3. Duodenoscopes
5.1.2.4. Enteroscopes
5.1.2.5. Endoscopic Ultrasound Scopes
5.1.2.6. Endoscopic Imaging Processors
5.1.2.7. Light Sources
5.1.2.8. Endoscopy Monitors and Displays
5.1.2.9. Insufflation Systems
5.1.2.10. Irrigation and Water-Jet Systems
5.1.3. Endotherapy and Therapeutic Accessories
5.1.3.1. Biopsy Forceps
5.1.3.2. Polypectomy Snares
5.1.3.3. Injection Needles
5.1.3.4. Hemostasis Clips
5.1.3.5. Tissue Closure Devices
5.1.3.6. Endoscopic Suturing Systems
5.1.3.7. Dilation Balloons
5.1.3.8. Guidewires
5.1.3.9. Retrieval Baskets and Nets
5.1.3.10. Electrosurgical Accessories
5.1.3.11. Hemostatic Devices
5.1.3.12. Gastrointestinal Stents
5.1.3.13. EUS and ERCP Accessories
5.1.4. Endoscope Reprocessing and Infection-Prevention Devices
5.1.4.1. Automated Endoscope Reprocessors
5.1.4.2. Endoscope Drying and Storage Systems
5.1.4.3. Leak Testing Systems
5.1.4.4. Cleaning Verification Technologies
5.1.4.5. Reprocessing Brushes and Accessories
5.1.4.6. Cleaning and High-Level Disinfection Systems
5.1.4.7. Endoscope Tracking and Traceability Solutions
5.1.5. GI Diagnostic, Capsule and Functional Testing Devices
5.1.5.1. Capsule Endoscopy Systems
5.1.5.2. Esophageal Manometry Systems
5.1.5.3. Anorectal Manometry Systems
5.1.5.4. pH and Impedance Monitoring Systems
5.1.5.5. Motility Testing Devices
5.1.5.6. Other Functional GI Diagnostic Devices
5.1.6. AI-Enabled and Digital Endoscopy Technologies
5.1.6.1. Computer-Aided Detection Systems
5.1.6.2. Computer-Aided Diagnosis and Characterization Systems
5.1.6.3. Lesion Measurement Technologies
5.1.6.4. Endoscopy Quality Analytics
5.1.6.5. Procedure Documentation Platforms
5.1.6.6. Digital Workflow and Data Integration Systems

What this section provides: This section identifies the product categories and subcategories expected to generate the largest revenue pools and strongest growth, while distinguishing capital equipment, recurring consumables, diagnostics, reprocessing infrastructure, and AI-enabled technologies.

6. U.S. Outpatient Gastroenterology Devices Market – By Application

6.1. Overview
6.1.1. Segment Share Analysis, By Application, 2025 & 2035 (%)
6.1.2. Colorectal Cancer Screening, Surveillance and Polyp Management
6.1.2.1. Screening Colonoscopy
6.1.2.2. Surveillance Colonoscopy
6.1.2.3. Diagnostic Colonoscopy
6.1.2.4. Polypectomy
6.1.2.5. Endoscopic Mucosal Resection
6.1.2.6. Advanced Colorectal Lesion Management
6.1.3. Upper Gastrointestinal Diagnosis and Therapy
6.1.3.1. GERD and Esophagitis Evaluation
6.1.3.2. Barrett’s Esophagus Surveillance
6.1.3.3. Dysphagia and Stricture Management
6.1.3.4. Peptic Ulcer Disease
6.1.3.5. Upper-GI Bleeding
6.1.3.6. Esophageal and Gastric Lesion Management
6.1.4. Pancreatobiliary and Advanced EUS Procedures
6.1.4.1. Endoscopic Ultrasound Diagnostics
6.1.4.2. EUS-Guided Tissue Acquisition
6.1.4.3. Pancreatic and Biliary Evaluation
6.1.4.4. Selected Outpatient ERCP Procedures
6.1.4.5. EUS-Guided Therapeutic Procedures
6.1.5. Inflammatory Bowel Disease, Lower-GI Disorders and GI Bleeding
6.1.5.1. Inflammatory Bowel Disease Surveillance
6.1.5.2. Lower-GI Bleeding Management
6.1.5.3. Diverticular Disease Evaluation
6.1.5.4. Chronic Lower-GI Disease Monitoring
6.1.6. Motility Disorders, Metabolic Endoscopy and Other Applications
6.1.6.1. Esophageal Motility Disorders
6.1.6.2. Anorectal and Pelvic Floor Disorders
6.1.6.3. Small-Bowel Evaluation
6.1.6.4. Bariatric and Metabolic Endoscopy
6.1.6.5. Third-Space Endoscopy
6.1.6.6. Foreign-Body Removal and Other GI Procedures

What this section provides: This section evaluates device demand by clinical use case and helps clients identify applications offering high procedure volume, increasing therapeutic intensity, favorable outpatient migration, and strong technology adoption potential.

7. U.S. Outpatient Gastroenterology Devices Market – By End User

7.1. Overview
7.1.1. Segment Share Analysis, By End User, 2025 & 2035 (%)
7.1.2. Gastroenterology-Focused Ambulatory Surgery Centers
7.1.2.1. Independent Physician-Owned GI ASCs
7.1.2.2. Corporate/Platform-Affiliated GI ASCs
7.1.2.3. Health-System Joint-Venture GI ASCs
7.1.3. Hospital Outpatient Departments
7.1.3.1. Community Hospital Outpatient Endoscopy Units
7.1.3.2. Tertiary Hospital Outpatient GI Units
7.1.3.3. Integrated Delivery Network Outpatient Centers
7.1.4. Office-Based Gastroenterology Clinics and Physician-Owned Endoscopy Centers
7.1.4.1. Independent Gastroenterology Practices
7.1.4.2. Multisite GI Physician Groups
7.1.4.3. Office-Based Diagnostic Endoscopy Facilities
7.1.5. Academic Medical Center Outpatient Programs and Specialty Referral Centers
7.1.5.1. Advanced Endoscopy Programs
7.1.5.2. Academic GI Procedure Centers
7.1.5.3. Tertiary Referral Endoscopy Centers
7.1.6. Specialty Diagnostic and Motility Centers
7.1.6.1. Capsule Endoscopy Centers
7.1.6.2. GI Motility Laboratories
7.1.6.3. Reflux and Functional GI Diagnostic Centers

What this section provides: This section explains which outpatient care settings generate device purchases, recurring consumable demand, capital replacement opportunities, and adoption of advanced GI technologies.

8. U.S. Outpatient Gastroenterology Devices Market – By Technology Type

8.1. Overview
8.1.1. Segment Share Analysis, By Technology Type, 2025 & 2035 (%)
8.1.2. Reusable Flexible Endoscopy Systems
8.1.2.1. Reusable Video Colonoscopy
8.1.2.2. Reusable Video Gastroscopy
8.1.2.3. Reusable Advanced Endoscopy Systems
8.1.3. Single-Use and Disposable Endoscopy Technologies
8.1.3.1. Single-Use Gastroscopes
8.1.3.2. Single-Use Colonoscopes
8.1.3.3. Single-Use Duodenoscopes
8.1.3.4. Disposable Endoscopy Accessories
8.1.4. High-Definition, 4K and Image-Enhanced Endoscopy
8.1.4.1. High-Definition Endoscopy
8.1.4.2. 4K Endoscopic Visualization
8.1.4.3. Narrow-Band and Multi-Light Imaging
8.1.4.4. Linked Color and Texture Enhancement
8.1.4.5. Digital Lesion Measurement Technologies
8.1.5. AI-Assisted and Software-Enabled Endoscopy
8.1.5.1. AI-Assisted Polyp Detection
8.1.5.2. AI-Assisted Lesion Characterization
8.1.5.3. AI-Assisted Quality Measurement
8.1.5.4. Automated Endoscopy Documentation
8.1.5.5. Procedure Analytics and Decision Support
8.1.6. Connected Reprocessing, Traceability and Workflow Technologies
8.1.6.1. Automated Reprocessing
8.1.6.2. Electronic Scope Tracking
8.1.6.3. Digital Cycle Documentation
8.1.6.4. Cleaning Verification and Quality Monitoring
8.1.6.5. Connected Endoscopy Workflow Systems

What this section provides: This section evaluates the major technology architectures reshaping outpatient gastroenterology, including reusable and disposable scopes, advanced visualization, AI, digital workflow, reprocessing automation, and traceability.

9. U.S. Outpatient Gastroenterology Devices Market: Outpatient Procedure Economics & Procurement Framework

9.1. Overview
9.2. ASC Versus Hospital Outpatient Department Procedure Economics
9.3. Capital Equipment Versus Procedure-Based Consumable Economics
9.4. Gastroenterology ASC Cost-per-Case Analysis
9.5. Endoscope Lifecycle Cost Analysis
9.5.1. Acquisition Cost
9.5.2. Preventive Maintenance
9.5.3. Scope Repair Cost
9.5.4. Backup Scope Requirements
9.5.5. Useful Life and Replacement Cycle
9.6. Reprocessing Economics Analysis
9.6.1. Labor Cost
9.6.2. Cleaning Chemistry
9.6.3. Water and Utility Consumption
9.6.4. Automated Reprocessor Capital Cost
9.6.5. Drying and Storage Cost
9.6.6. Infection-Control Compliance Cost
9.7. Reusable Versus Single-Use Endoscope Economic Comparison
9.8. GPO and IDN Contracting Influence
9.9. Independent GI Practice Procurement Behavior
9.10. Physician-Owned ASC Purchasing Decision Framework
9.11. Capital Leasing and Equipment Financing Trends
9.12. Service Contract and Equipment Uptime Economics
9.13. Vendor Standardization and Bundled Contracting
9.14. Reimbursement Capture and Procedure Profitability
9.15. Room Turnover and Endoscopy Suite Throughput Economics
9.16. Value-Based Procurement Decision Matrix

What this section provides: This section explains how outpatient GI devices are economically evaluated and purchased, including cost per case, capital-versus-consumable trade-offs, reprocessing costs, service contracts, GPO influence, reimbursement, physician ownership, and endoscopy-suite productivity.

10. U.S. Outpatient Gastroenterology Devices Market – By Geography

10.1. Introduction
10.1.1. Segment Share Analysis, By Geography, 2025 & 2035 (%)
10.1.2. Regional Market Size and Forecast, 2021–2035 (US$ Billion)
10.1.3. Regional Outpatient GI Procedure Volume Analysis
10.1.4. Regional ASC and HOPD Infrastructure Analysis
10.1.5. Regional Colorectal Screening and GI Disease Burden Analysis
10.1.6. Regional Reimbursement and Site-of-Care Dynamics
10.1.7. Regional Technology Adoption Analysis
10.1.8. Regional Procurement and Competitive Landscape
10.2. West Region
10.2.1. Regional Overview & Trends
10.2.2. West Region Key Manufacturers and Outpatient GI Procurement Ecosystem
10.2.3. West Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.2.4. West Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.5. West Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.6. West Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.7. West Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.8. West Region ASC Infrastructure, Procedure Volume and Procurement Analysis
10.2.9. California
10.2.9.1. Overview
10.2.9.2. California Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.9.3. California Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.9.4. California Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.9.5. California Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.9.6. California Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.2.10. Washington
10.2.10.1. Overview
10.2.10.2. Washington Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.10.3. Washington Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.10.4. Washington Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.10.5. Washington Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.10.6. Washington Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.2.11. Arizona
10.2.11.1. Overview
10.2.11.2. Arizona Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.11.3. Arizona Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.11.4. Arizona Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.11.5. Arizona Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.11.6. Arizona Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.2.12. Colorado
10.2.12.1. Overview
10.2.12.2. Colorado Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.12.3. Colorado Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.12.4. Colorado Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.12.5. Colorado Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.12.6. Colorado Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.2.13. Oregon
10.2.13.1. Overview
10.2.13.2. Oregon Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.13.3. Oregon Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.13.4. Oregon Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.13.5. Oregon Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.13.6. Oregon Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.2.14. Utah
10.2.14.1. Overview
10.2.14.2. Utah Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.14.3. Utah Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.14.4. Utah Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.14.5. Utah Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.14.6. Utah Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.2.15. Nevada
10.2.15.1. Overview
10.2.15.2. Nevada Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.15.3. Nevada Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.15.4. Nevada Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.15.5. Nevada Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.15.6. Nevada Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.2.16. New Mexico
10.2.16.1. Overview
10.2.16.2. New Mexico Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.16.3. New Mexico Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.16.4. New Mexico Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.16.5. New Mexico Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.16.6. New Mexico Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.2.17. Idaho
10.2.17.1. Overview
10.2.17.2. Idaho Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.17.3. Idaho Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.17.4. Idaho Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.17.5. Idaho Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.17.6. Idaho Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.2.18. Montana
10.2.18.1. Overview
10.2.18.2. Montana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.18.3. Montana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.18.4. Montana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.18.5. Montana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.18.6. Montana Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.2.19. Wyoming
10.2.19.1. Overview
10.2.19.2. Wyoming Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.19.3. Wyoming Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.19.4. Wyoming Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.19.5. Wyoming Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.19.6. Wyoming Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.2.20. Alaska
10.2.20.1. Overview
10.2.20.2. Alaska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.20.3. Alaska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.20.4. Alaska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.20.5. Alaska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.20.6. Alaska Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.2.21. Hawaii
10.2.21.1. Overview
10.2.21.2. Hawaii Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.2.21.3. Hawaii Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.2.21.4. Hawaii Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.2.21.5. Hawaii Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.2.21.6. Hawaii Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.3. Northeast Region
10.3.1. Regional Overview & Trends
10.3.2. Northeast Region Key Manufacturers and Outpatient GI Procurement Ecosystem
10.3.3. Northeast Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.3.4. Northeast Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.5. Northeast Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.6. Northeast Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.7. Northeast Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.8. Northeast Region ASC Infrastructure, Procedure Volume and Procurement Analysis
10.3.9. New York
10.3.9.1. Overview
10.3.9.2. New York Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.9.3. New York Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.9.4. New York Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.9.5. New York Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.9.6. New York Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.3.10. Massachusetts
10.3.10.1. Overview
10.3.10.2. Massachusetts Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.10.3. Massachusetts Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.10.4. Massachusetts Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.10.5. Massachusetts Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.10.6. Massachusetts Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.3.11. New Jersey
10.3.11.1. Overview
10.3.11.2. New Jersey Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.11.3. New Jersey Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.11.4. New Jersey Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.11.5. New Jersey Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.11.6. New Jersey Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.3.12. Pennsylvania
10.3.12.1. Overview
10.3.12.2. Pennsylvania Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.12.3. Pennsylvania Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.12.4. Pennsylvania Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.12.5. Pennsylvania Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.12.6. Pennsylvania Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.3.13. Connecticut
10.3.13.1. Overview
10.3.13.2. Connecticut Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.13.3. Connecticut Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.13.4. Connecticut Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.13.5. Connecticut Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.13.6. Connecticut Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.3.14. Maine
10.3.14.1. Overview
10.3.14.2. Maine Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.14.3. Maine Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.14.4. Maine Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.14.5. Maine Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.14.6. Maine Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.3.15. Vermont
10.3.15.1. Overview
10.3.15.2. Vermont Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.15.3. Vermont Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.15.4. Vermont Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.15.5. Vermont Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.15.6. Vermont Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.3.16. New Hampshire
10.3.16.1. Overview
10.3.16.2. New Hampshire Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.16.3. New Hampshire Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.16.4. New Hampshire Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.16.5. New Hampshire Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.16.6. New Hampshire Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.3.17. Rhode Island
10.3.17.1. Overview
10.3.17.2. Rhode Island Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.17.3. Rhode Island Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.17.4. Rhode Island Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.17.5. Rhode Island Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.17.6. Rhode Island Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.3.18. Delaware
10.3.18.1. Overview
10.3.18.2. Delaware Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.3.18.3. Delaware Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.3.18.4. Delaware Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.3.18.5. Delaware Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.3.18.6. Delaware Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.4. South Region
10.4.1. Regional Overview & Trends
10.4.2. South Region Key Manufacturers and Outpatient GI Procurement Ecosystem
10.4.3. South Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.4.4. South Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.5. South Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.6. South Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.7. South Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.8. South Region ASC Infrastructure, Procedure Volume and Procurement Analysis
10.4.9. Texas
10.4.9.1. Overview
10.4.9.2. Texas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.9.3. Texas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.9.4. Texas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.9.5. Texas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.9.6. Texas Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.4.10. Florida
10.4.10.1. Overview
10.4.10.2. Florida Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.10.3. Florida Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.10.4. Florida Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.10.5. Florida Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.10.6. Florida Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.4.11. Georgia
10.4.11.1. Overview
10.4.11.2. Georgia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.11.3. Georgia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.11.4. Georgia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.11.5. Georgia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.11.6. Georgia Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.4.12. North Carolina
10.4.12.1. Overview
10.4.12.2. North Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.12.3. North Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.12.4. North Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.12.5. North Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.12.6. North Carolina Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.4.13. Tennessee
10.4.13.1. Overview
10.4.13.2. Tennessee Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.13.3. Tennessee Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.13.4. Tennessee Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.13.5. Tennessee Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.13.6. Tennessee Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.4.14. South Carolina
10.4.14.1. Overview
10.4.14.2. South Carolina Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.14.3. South Carolina Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.14.4. South Carolina Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.14.5. South Carolina Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.14.6. South Carolina Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.4.15. Alabama
10.4.15.1. Overview
10.4.15.2. Alabama Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.15.3. Alabama Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.15.4. Alabama Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.15.5. Alabama Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.15.6. Alabama Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.4.16. Mississippi
10.4.16.1. Overview
10.4.16.2. Mississippi Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.16.3. Mississippi Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.16.4. Mississippi Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.16.5. Mississippi Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.16.6. Mississippi Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.4.17. Louisiana
10.4.17.1. Overview
10.4.17.2. Louisiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.17.3. Louisiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.17.4. Louisiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.17.5. Louisiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.17.6. Louisiana Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.4.18. Arkansas
10.4.18.1. Overview
10.4.18.2. Arkansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.18.3. Arkansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.18.4. Arkansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.18.5. Arkansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.18.6. Arkansas Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.4.19. Kentucky
10.4.19.1. Overview
10.4.19.2. Kentucky Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.19.3. Kentucky Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.19.4. Kentucky Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.19.5. Kentucky Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.19.6. Kentucky Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.4.20. Oklahoma
10.4.20.1. Overview
10.4.20.2. Oklahoma Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.20.3. Oklahoma Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.20.4. Oklahoma Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.20.5. Oklahoma Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.20.6. Oklahoma Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.4.21. Virginia
10.4.21.1. Overview
10.4.21.2. Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.21.3. Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.21.4. Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.21.5. Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.21.6. Virginia Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.4.22. Maryland
10.4.22.1. Overview
10.4.22.2. Maryland Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.22.3. Maryland Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.22.4. Maryland Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.22.5. Maryland Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.22.6. Maryland Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.4.23. West Virginia
10.4.23.1. Overview
10.4.23.2. West Virginia Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.4.23.3. West Virginia Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.4.23.4. West Virginia Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.4.23.5. West Virginia Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.4.23.6. West Virginia Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.5. Midwest Region
10.5.1. Regional Overview & Trends
10.5.2. Midwest Region Key Manufacturers and Outpatient GI Procurement Ecosystem
10.5.3. Midwest Region Market Size and Forecast, By State, 2021–2035 (US$ Billion)
10.5.4. Midwest Region Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.5. Midwest Region Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.6. Midwest Region Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.7. Midwest Region Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.8. Midwest Region ASC Infrastructure, Procedure Volume and Procurement Analysis
10.5.9. Illinois
10.5.9.1. Overview
10.5.9.2. Illinois Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.9.3. Illinois Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.9.4. Illinois Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.9.5. Illinois Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.9.6. Illinois Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.5.10. Ohio
10.5.10.1. Overview
10.5.10.2. Ohio Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.10.3. Ohio Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.10.4. Ohio Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.10.5. Ohio Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.10.6. Ohio Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.5.11. Michigan
10.5.11.1. Overview
10.5.11.2. Michigan Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.11.3. Michigan Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.11.4. Michigan Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.11.5. Michigan Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.11.6. Michigan Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.5.12. Minnesota
10.5.12.1. Overview
10.5.12.2. Minnesota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.12.3. Minnesota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.12.4. Minnesota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.12.5. Minnesota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.12.6. Minnesota Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.5.13. Indiana
10.5.13.1. Overview
10.5.13.2. Indiana Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.13.3. Indiana Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.13.4. Indiana Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.13.5. Indiana Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.13.6. Indiana Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.5.14. Wisconsin
10.5.14.1. Overview
10.5.14.2. Wisconsin Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.14.3. Wisconsin Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.14.4. Wisconsin Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.14.5. Wisconsin Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.14.6. Wisconsin Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.5.15. Missouri
10.5.15.1. Overview
10.5.15.2. Missouri Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.15.3. Missouri Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.15.4. Missouri Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.15.5. Missouri Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.15.6. Missouri Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.5.16. Iowa
10.5.16.1. Overview
10.5.16.2. Iowa Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.16.3. Iowa Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.16.4. Iowa Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.16.5. Iowa Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.16.6. Iowa Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.5.17. Kansas
10.5.17.1. Overview
10.5.17.2. Kansas Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.17.3. Kansas Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.17.4. Kansas Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.17.5. Kansas Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.17.6. Kansas Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.5.18. Nebraska
10.5.18.1. Overview
10.5.18.2. Nebraska Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.18.3. Nebraska Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.18.4. Nebraska Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.18.5. Nebraska Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.18.6. Nebraska Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.5.19. North Dakota
10.5.19.1. Overview
10.5.19.2. North Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.19.3. North Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.19.4. North Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.19.5. North Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.19.6. North Dakota Outpatient GI Procedure, ASC Infrastructure and Procurement Insights
10.5.20. South Dakota
10.5.20.1. Overview
10.5.20.2. South Dakota Market Size and Forecast, By Product Category, 2021–2035 (US$ Billion)
10.5.20.3. South Dakota Market Size and Forecast, By Application, 2021–2035 (US$ Billion)
10.5.20.4. South Dakota Market Size and Forecast, By End User, 2021–2035 (US$ Billion)
10.5.20.5. South Dakota Market Size and Forecast, By Technology Type, 2021–2035 (US$ Billion)
10.5.20.6. South Dakota Outpatient GI Procedure, ASC Infrastructure and Procurement Insights

What this section provides: This section delivers detailed regional and all-state market analysis, allowing clients to identify outpatient GI procedure hubs, ASC expansion markets, colorectal-screening demand centers, technology-adoption hotspots, and state-level commercial opportunities across the West, Northeast, South, and Midwest.

11. U.S. Outpatient Gastroenterology Devices Market: Competitive Landscape & Company Profiles

11.1. Market Share Analysis, 2025
11.2. Competitive Intensity Analysis
11.3. Company Positioning Matrix
11.3.1. Leaders
11.3.2. Challengers
11.3.3. Innovators
11.3.4. Emerging Players
11.4. Portfolio Positioning Analysis
11.4.1. Endoscopy Platform Leaders
11.4.2. Endotherapy and Consumables Leaders
11.4.3. Single-Use Endoscopy Innovators
11.4.4. Reprocessing and Infection-Prevention Leaders
11.4.5. AI and Digital Endoscopy Innovators
11.4.6. GI Diagnostic and Motility Technology Specialists
11.5. Company Profiles
11.5.1. Olympus Corporation
11.5.2. Boston Scientific Corporation
11.5.3. Medtronic plc
11.5.4. FUJIFILM Healthcare Americas Corporation
11.5.5. PENTAX Medical / HOYA Corporation
11.5.6. STERIS plc
11.5.7. Ambu A/S
11.5.8. Cook Medical
11.5.9. CONMED Corporation
11.5.10. KARL STORZ SE & Co. KG
11.5.11. ERBE Elektromedizin GmbH / ERBE USA
11.5.12. Micro-Tech Endoscopy USA
11.5.13. Merit Medical Systems, Inc.
11.5.14. Ovesco Endoscopy USA
11.5.15. Creo Medical Group plc
11.5.16. Laborie Medical Technologies
11.5.17. Diversatek Healthcare
11.5.18. CapsoVision, Inc.
11.5.19. AnX Robotica
11.5.20. EvoEndo, Inc.
11.5.21. EndoGastric Solutions, Inc.
11.5.22. Lumendi Ltd.
11.5.23. Cosmo Pharmaceuticals / Cosmo Intelligent Medical Devices
11.5.24. EndoQuest Robotics, Inc.
11.6. Competitive Benchmarking
11.6.1. U.S. Product Portfolio Breadth
11.6.2. Outpatient and ASC Market Presence
11.6.3. Installed Endoscopy Platform Base
11.6.4. Therapeutic Accessory Strength
11.6.5. AI and Digital Capabilities
11.6.6. Single-Use Endoscopy Positioning
11.6.7. Reprocessing and Infection-Prevention Capabilities
11.6.8. Service and Repair Infrastructure
11.6.9. Physician Training and Clinical Education
11.6.10. FDA Pipeline and Innovation Strength

Note: Each company profile will include company overview, outpatient gastroenterology device portfolio, U.S. market strategy, product positioning, financial and commercial positioning where available, FDA/regulatory updates, clinical pipeline, partnerships, M&A activity, technology developments, and recent strategic developments.

What this section provides: This section gives clients competitor benchmarking, market-share visibility, portfolio positioning, technology direction, installed-base strategy, innovation strength, and strategic intelligence on leading and emerging outpatient gastroenterology device companies.

12. U.S. Outpatient Gastroenterology Devices Market: Future Market Outlook, 2026–2035

12.1. Scenario Analysis
12.1.1. Optimistic Scenario
12.1.2. Realistic Scenario
12.1.3. Pessimistic Scenario
12.2. Disruptive Technologies Impact
12.2.1. AI-Assisted Colonoscopy
12.2.2. AI-Based Lesion Characterization
12.2.3. Advanced Therapeutic Endoscopy
12.2.4. Single-Use Endoscopy Platforms
12.2.5. Next-Generation HD and 4K Visualization
12.2.6. Image-Enhanced Endoscopy
12.2.7. Robotic and Computer-Assisted Endoscopy
12.2.8. Connected Reprocessing and Scope Traceability
12.2.9. Advanced Capsule Endoscopy
12.2.10. Bariatric and Metabolic Endoscopy
12.3. Future Procedure Migration to Outpatient Settings
12.4. Future ASC Infrastructure Expansion
12.5. Future Endoscopy Installed-Base Replacement Cycle
12.6. Emerging Business Trends
12.7. Physician Practice Consolidation Impact
12.8. Private Equity and GI Platform Expansion
12.9. Future Reimbursement and Site-of-Care Outlook
12.10. Business Opportunities for Startups and Existing Players
12.11. Investment Prioritization Matrix
12.12. Technology Adoption Roadmap, 2026–2035

What this section provides: This section prepares clients for changes in outpatient GI procedure migration, AI adoption, therapeutic endoscopy, single-use devices, ASC expansion, consolidation, investment priorities, and potential market scenarios through 2035.

13. U.S. Outpatient Gastroenterology Devices Market: Strategic Recommendations

13.1. Recommendations for Gastroenterology Device Manufacturers
13.2. Recommendations for Endoscopy Platform Companies
13.3. Recommendations for Ambulatory Surgery Center Operators
13.4. Recommendations for Hospital Outpatient Departments
13.5. Recommendations for Gastroenterology Physician Groups
13.6. Recommendations for Investors and Private Equity Firms
13.7. Recommendations for Distributors and Channel Partners
13.8. Recommendations for AI and Digital Endoscopy Companies
13.9. Recommendations for Single-Use Endoscopy Manufacturers
13.10. Recommendations for New Entrants and Startups
13.11. Go-to-Market Strategy Considerations
13.12. U.S. State Expansion Strategy
13.13. Product Positioning and Portfolio Expansion Guidance
13.14. Pricing and Contracting Strategy
13.15. ASC-Specific Commercialization Strategy
13.16. M&A and Partnership Opportunity Framework

What this section provides: This section converts market intelligence into actionable guidance for product development, commercialization, ASC penetration, state expansion, pricing, partnerships, investment decisions, portfolio development, and competitive differentiation.

14. U.S. Outpatient Gastroenterology Devices Market: Disclaimer

14.1. Scope Limitation
14.2. Data Use Limitation
14.3. Market Size Estimation Limitation
14.4. Forecasting Limitation
14.5. Regulatory and Reimbursement Information Limitation
14.6. Company and Competitive Intelligence Limitation
14.7. Legal Disclaimer
14.8. Third-Party Data Disclaimer

What this section provides: This section clarifies the report’s analytical boundaries, market-sizing limitations, forecasting assumptions, regulatory and reimbursement limitations, competitive-intelligence boundaries, legal conditions, and data-use terms.

 

List of Tables

TABLE 1: List of Data Sources
TABLE 2: U.S. Outpatient Gastroenterology Devices Market: Market Definition and Scope
TABLE 3: U.S. Outpatient Gastroenterology Devices Market: Research Methodology Framework
TABLE 4: U.S. Outpatient Gastroenterology Devices Market: Primary and Secondary Data Collection Framework
TABLE 5: U.S. Outpatient Gastroenterology Devices Market: Key Assumptions
TABLE 6: U.S. Outpatient Gastroenterology Devices Market: Market Ecosystem Overview
TABLE 7: U.S. Outpatient Gastroenterology Devices Market: Stakeholder Analysis
TABLE 8: U.S. Outpatient Gastroenterology Devices Market: Executive Summary Snapshot, 2025
TABLE 9: U.S. Outpatient Gastroenterology Devices Market: Analyst Viewpoint Summary
TABLE 10: U.S. Outpatient Gastroenterology Devices Market: Market Attractiveness Index
TABLE 11: U.S. Outpatient Gastroenterology Devices Market: Historical Market Size, 2021–2024 (US$ Billion)
TABLE 12: U.S. Outpatient Gastroenterology Devices Market: Base Year Market Positioning, 2025 (US$ Billion)
TABLE 13: U.S. Outpatient Gastroenterology Devices Market: Forecast Market Size, 2026–2035 (US$ Billion)
TABLE 14: U.S. Outpatient Gastroenterology Devices Market: Year-wise Market Size, 2021–2035 (US$ Billion)
TABLE 15: U.S. Outpatient Gastroenterology Devices Market: CAGR Analysis, 2026–2035
TABLE 16: U.S. Outpatient Gastroenterology Devices Market: Leading and Fastest-Growing Segment Analysis
TABLE 17: U.S. Outpatient Gastroenterology Devices Market: High-Growth Opportunity Areas
TABLE 18: U.S. Outpatient Gastroenterology Devices Market: Drivers; Impact Analysis
TABLE 19: U.S. Outpatient Gastroenterology Devices Market: Restraints; Impact Analysis
TABLE 20: U.S. Outpatient Gastroenterology Devices Market: Opportunities; Impact Analysis
TABLE 21: U.S. Outpatient Gastroenterology Devices Market: Challenges; Impact Analysis
TABLE 22: U.S. Outpatient Gastroenterology Devices Market: Patent & Innovation Analysis, 2021–2025
TABLE 23: U.S. Outpatient Gastroenterology Devices Market: Outpatient GI Clinical Workflow Economics Matrix
TABLE 24: U.S. Outpatient Gastroenterology Devices Market: ASC Capital Procurement Behavior Matrix
TABLE 25: U.S. Outpatient Gastroenterology Devices Market: Endoscopy Installed-Base Replacement Cycle Analysis
TABLE 26: U.S. Outpatient Gastroenterology Devices Market: Procedure Volume–Device Consumption Correlation Analysis
TABLE 27: U.S. Outpatient Gastroenterology Devices Market: PESTEL Analysis
TABLE 28: U.S. Outpatient Gastroenterology Devices Market: Porter’s Five Forces Analysis
TABLE 29: U.S. Outpatient Gastroenterology Devices Market: Pricing Trend Analysis by Region, 2025–2035
TABLE 30: U.S. Outpatient Gastroenterology Devices Market: Value Chain Analysis
TABLE 31: U.S. Outpatient Gastroenterology Devices Market: Supply Chain Analysis
TABLE 32: U.S. Outpatient Gastroenterology Devices Market: U.S. Endoscopy Installed-Base Analysis
TABLE 33: U.S. Outpatient Gastroenterology Devices Market: Digitalization and Connected Endoscopy Impact
TABLE 34: U.S. Outpatient Gastroenterology Devices Market: AI Adoption Landscape
TABLE 35: U.S. Outpatient Gastroenterology Devices Market: Application & Innovation Landscape
TABLE 36: U.S. Outpatient Gastroenterology Devices Market: FDA Regulatory Framework Analysis
TABLE 37: U.S. Outpatient Gastroenterology Devices Market: CMS Reimbursement and ASC Coverage Landscape
TABLE 38: U.S. Outpatient Gastroenterology Devices Market: Medicare ASC Versus HOPD Payment Economics
TABLE 39: U.S. Outpatient Gastroenterology Devices Market: Commercial Payer Site-of-Care Policies
TABLE 40: U.S. Outpatient Gastroenterology Devices Market: Infection Prevention and Endoscope Reprocessing Standards
TABLE 41: U.S. Outpatient Gastroenterology Devices Market: Import/Export Restrictions & Tariff Impact
TABLE 42: U.S. Outpatient Gastroenterology Devices Market: Government Colorectal Cancer Screening Initiatives
TABLE 43: U.S. Outpatient Gastroenterology Devices Market: Sustainability Impact of Reusable Versus Single-Use Devices
TABLE 44: U.S. Outpatient Gastroenterology Devices Market: Outpatient Value Analysis Decision Framework
TABLE 45: U.S. Outpatient Gastroenterology Devices Market: Product Category Snapshot, 2025
TABLE 46: Segment Dashboard; Definition and Scope, by Product Category
TABLE 47: U.S. Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 48: U.S. Outpatient Gastroenterology Devices Market: Segment Share Analysis, by Product Category, 2025 & 2035 (%)
TABLE 49: U.S. Outpatient Gastroenterology Devices Market: Endoscopes and Visualization Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 50: U.S. Outpatient Gastroenterology Devices Market: Endotherapy and Therapeutic Accessories Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 51: U.S. Outpatient Gastroenterology Devices Market: Endoscope Reprocessing and Infection-Prevention Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 52: U.S. Outpatient Gastroenterology Devices Market: GI Diagnostic, Capsule and Functional Testing Devices Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 53: U.S. Outpatient Gastroenterology Devices Market: AI-Enabled and Digital Endoscopy Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 54: U.S. Outpatient Gastroenterology Devices Market: Application Snapshot, 2025
TABLE 55: Segment Dashboard; Definition and Scope, by Application
TABLE 56: U.S. Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 57: U.S. Outpatient Gastroenterology Devices Market: Segment Share Analysis, by Application, 2025 & 2035 (%)
TABLE 58: U.S. Outpatient Gastroenterology Devices Market: Colorectal Cancer Screening, Surveillance and Polyp Management Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 59: U.S. Outpatient Gastroenterology Devices Market: Upper Gastrointestinal Diagnosis and Therapy Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 60: U.S. Outpatient Gastroenterology Devices Market: Pancreatobiliary and Advanced EUS Procedures Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 61: U.S. Outpatient Gastroenterology Devices Market: Inflammatory Bowel Disease, Lower-GI Disorders and GI Bleeding Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 62: U.S. Outpatient Gastroenterology Devices Market: Motility Disorders, Metabolic Endoscopy and Other Applications Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 63: U.S. Outpatient Gastroenterology Devices Market: End User Snapshot, 2025
TABLE 64: Segment Dashboard; Definition and Scope, by End User
TABLE 65: U.S. Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 66: U.S. Outpatient Gastroenterology Devices Market: Segment Share Analysis, by End User, 2025 & 2035 (%)
TABLE 67: U.S. Outpatient Gastroenterology Devices Market: Gastroenterology-Focused Ambulatory Surgery Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 68: U.S. Outpatient Gastroenterology Devices Market: Hospital Outpatient Departments Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 69: U.S. Outpatient Gastroenterology Devices Market: Office-Based Gastroenterology Clinics and Physician-Owned Endoscopy Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 70: U.S. Outpatient Gastroenterology Devices Market: Academic Medical Center Outpatient Programs and Specialty Referral Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 71: U.S. Outpatient Gastroenterology Devices Market: Specialty Diagnostic and Motility Centers Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 72: U.S. Outpatient Gastroenterology Devices Market: Technology Type Snapshot, 2025
TABLE 73: Segment Dashboard; Definition and Scope, by Technology Type
TABLE 74: U.S. Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 75: U.S. Outpatient Gastroenterology Devices Market: Segment Share Analysis, by Technology Type, 2025 & 2035 (%)
TABLE 76: U.S. Outpatient Gastroenterology Devices Market: Reusable Flexible Endoscopy Systems Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 77: U.S. Outpatient Gastroenterology Devices Market: Single-Use and Disposable Endoscopy Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 78: U.S. Outpatient Gastroenterology Devices Market: High-Definition, 4K and Image-Enhanced Endoscopy Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 79: U.S. Outpatient Gastroenterology Devices Market: AI-Assisted and Software-Enabled Endoscopy Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 80: U.S. Outpatient Gastroenterology Devices Market: Connected Reprocessing, Traceability and Workflow Technologies Market Size and Forecast, 2021–2035 (US$ Billion)
TABLE 81: U.S. Outpatient Gastroenterology Devices Market: Outpatient Procedure Economics & Procurement Snapshot, 2025
TABLE 82: U.S. Outpatient Gastroenterology Devices Market: ASC Versus Hospital Outpatient Department Procedure Economics
TABLE 83: U.S. Outpatient Gastroenterology Devices Market: Capital Equipment Versus Procedure-Based Consumable Economics
TABLE 84: U.S. Outpatient Gastroenterology Devices Market: Gastroenterology ASC Cost-per-Case Analysis
TABLE 85: U.S. Outpatient Gastroenterology Devices Market: Endoscope Lifecycle Cost Analysis
TABLE 86: U.S. Outpatient Gastroenterology Devices Market: Reprocessing Economics Analysis
TABLE 87: U.S. Outpatient Gastroenterology Devices Market: Reusable Versus Single-Use Endoscope Economic Comparison
TABLE 88: U.S. Outpatient Gastroenterology Devices Market: GPO and IDN Contracting Influence
TABLE 89: U.S. Outpatient Gastroenterology Devices Market: Independent GI Practice Procurement Behavior
TABLE 90: U.S. Outpatient Gastroenterology Devices Market: Physician-Owned ASC Purchasing Decision Framework
TABLE 91: U.S. Outpatient Gastroenterology Devices Market: Capital Leasing, Service Contract and Equipment Uptime Economics
TABLE 92: U.S. Outpatient Gastroenterology Devices Market: Room Turnover and Endoscopy Suite Throughput Economics
TABLE 93: U.S. Outpatient Gastroenterology Devices Market: Value-Based Procurement Decision Matrix
TABLE 94: U.S. Outpatient Gastroenterology Devices Market: Regional Snapshot, 2025
TABLE 95: U.S. Outpatient Gastroenterology Devices Market: Segment Dashboard; Definition and Scope, by Geography
TABLE 96: U.S. Outpatient Gastroenterology Devices Market, by Geography, 2021–2035 (US$ Billion)
TABLE 97: U.S. Outpatient Gastroenterology Devices Market: Regional Share Analysis, 2025 & 2035 (%)
TABLE 98: U.S. Outpatient Gastroenterology Devices Market: Regional Outpatient GI Procedure Volume, ASC Infrastructure and Reimbursement Analysis
TABLE 99: West Region U.S. Outpatient Gastroenterology Devices Market: Regional Overview and Trends
TABLE 100: West Region U.S. Outpatient Gastroenterology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 101: West Region U.S. Outpatient Gastroenterology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 102: West Region U.S. Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 103: West Region U.S. Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 104: West Region U.S. Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 105: West Region U.S. Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 106: California Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 107: California Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 108: California Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 109: California Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 110: Washington Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 111: Washington Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 112: Washington Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 113: Washington Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 114: Arizona Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 115: Arizona Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 116: Arizona Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 117: Arizona Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 118: Colorado Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 119: Colorado Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 120: Colorado Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 121: Colorado Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 122: Oregon Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 123: Oregon Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 124: Oregon Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 125: Oregon Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 126: Utah Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 127: Utah Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 128: Utah Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 129: Utah Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 130: Nevada Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 131: Nevada Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 132: Nevada Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 133: Nevada Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 134: New Mexico Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 135: New Mexico Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 136: New Mexico Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 137: New Mexico Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 138: Idaho Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 139: Idaho Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 140: Idaho Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 141: Idaho Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 142: Montana Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 143: Montana Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 144: Montana Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 145: Montana Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 146: Wyoming Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 147: Wyoming Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 148: Wyoming Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 149: Wyoming Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 150: Alaska Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 151: Alaska Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 152: Alaska Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 153: Alaska Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 154: Hawaii Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 155: Hawaii Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 156: Hawaii Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 157: Hawaii Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 158: Northeast Region U.S. Outpatient Gastroenterology Devices Market: Regional Overview and Trends
TABLE 159: Northeast Region U.S. Outpatient Gastroenterology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 160: Northeast Region U.S. Outpatient Gastroenterology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 161: Northeast Region U.S. Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 162: Northeast Region U.S. Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 163: Northeast Region U.S. Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 164: Northeast Region U.S. Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 165: New York Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 166: New York Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 167: New York Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 168: New York Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 169: Massachusetts Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 170: Massachusetts Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 171: Massachusetts Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 172: Massachusetts Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 173: New Jersey Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 174: New Jersey Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 175: New Jersey Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 176: New Jersey Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 177: Pennsylvania Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 178: Pennsylvania Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 179: Pennsylvania Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 180: Pennsylvania Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 181: Connecticut Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 182: Connecticut Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 183: Connecticut Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 184: Connecticut Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 185: Maine Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 186: Maine Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 187: Maine Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 188: Maine Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 189: Vermont Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 190: Vermont Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 191: Vermont Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 192: Vermont Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 193: New Hampshire Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 194: New Hampshire Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 195: New Hampshire Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 196: New Hampshire Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 197: Rhode Island Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 198: Rhode Island Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 199: Rhode Island Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 200: Rhode Island Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 201: Delaware Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 202: Delaware Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 203: Delaware Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 204: Delaware Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 205: South Region U.S. Outpatient Gastroenterology Devices Market: Regional Overview and Trends
TABLE 206: South Region U.S. Outpatient Gastroenterology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 207: South Region U.S. Outpatient Gastroenterology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 208: South Region U.S. Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 209: South Region U.S. Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 210: South Region U.S. Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 211: South Region U.S. Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 212: Texas Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 213: Texas Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 214: Texas Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 215: Texas Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 216: Florida Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 217: Florida Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 218: Florida Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 219: Florida Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 220: Georgia Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 221: Georgia Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 222: Georgia Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 223: Georgia Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 224: North Carolina Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 225: North Carolina Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 226: North Carolina Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 227: North Carolina Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 228: Tennessee Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 229: Tennessee Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 230: Tennessee Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 231: Tennessee Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 232: South Carolina Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 233: South Carolina Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 234: South Carolina Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 235: South Carolina Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 236: Alabama Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 237: Alabama Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 238: Alabama Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 239: Alabama Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 240: Mississippi Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 241: Mississippi Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 242: Mississippi Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 243: Mississippi Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 244: Louisiana Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 245: Louisiana Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 246: Louisiana Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 247: Louisiana Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 248: Arkansas Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 249: Arkansas Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 250: Arkansas Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 251: Arkansas Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 252: Kentucky Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 253: Kentucky Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 254: Kentucky Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 255: Kentucky Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 256: Oklahoma Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 257: Oklahoma Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 258: Oklahoma Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 259: Oklahoma Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 260: Virginia Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 261: Virginia Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 262: Virginia Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 263: Virginia Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 264: Maryland Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 265: Maryland Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 266: Maryland Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 267: Maryland Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 268: West Virginia Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 269: West Virginia Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 270: West Virginia Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 271: West Virginia Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 272: Midwest Region U.S. Outpatient Gastroenterology Devices Market: Regional Overview and Trends
TABLE 273: Midwest Region U.S. Outpatient Gastroenterology Devices Market: Key Manufacturers and Procurement Ecosystem
TABLE 274: Midwest Region U.S. Outpatient Gastroenterology Devices Market, by State, 2021–2035 (US$ Billion)
TABLE 275: Midwest Region U.S. Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 276: Midwest Region U.S. Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 277: Midwest Region U.S. Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 278: Midwest Region U.S. Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 279: Illinois Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 280: Illinois Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 281: Illinois Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 282: Illinois Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 283: Ohio Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 284: Ohio Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 285: Ohio Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 286: Ohio Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 287: Michigan Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 288: Michigan Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 289: Michigan Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 290: Michigan Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 291: Minnesota Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 292: Minnesota Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 293: Minnesota Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 294: Minnesota Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 295: Indiana Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 296: Indiana Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 297: Indiana Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 298: Indiana Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 299: Wisconsin Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 300: Wisconsin Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 301: Wisconsin Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 302: Wisconsin Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 303: Missouri Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 304: Missouri Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 305: Missouri Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 306: Missouri Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 307: Iowa Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 308: Iowa Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 309: Iowa Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 310: Iowa Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 311: Kansas Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 312: Kansas Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 313: Kansas Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 314: Kansas Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 315: Nebraska Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 316: Nebraska Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 317: Nebraska Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 318: Nebraska Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 319: North Dakota Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 320: North Dakota Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 321: North Dakota Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 322: North Dakota Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 323: South Dakota Outpatient Gastroenterology Devices Market, by Product Category, 2021–2035 (US$ Billion)
TABLE 324: South Dakota Outpatient Gastroenterology Devices Market, by Application, 2021–2035 (US$ Billion)
TABLE 325: South Dakota Outpatient Gastroenterology Devices Market, by End User, 2021–2035 (US$ Billion)
TABLE 326: South Dakota Outpatient Gastroenterology Devices Market, by Technology Type, 2021–2035 (US$ Billion)
TABLE 327: U.S. Outpatient Gastroenterology Devices Market: Competitive Landscape Snapshot, 2025
TABLE 328: U.S. Outpatient Gastroenterology Devices Market: Key Company Market Share Analysis, 2025
TABLE 329: U.S. Outpatient Gastroenterology Devices Market: Company Positioning Matrix
TABLE 330: U.S. Outpatient Gastroenterology Devices Market: Product Portfolio Benchmarking of Key Players
TABLE 331: U.S. Outpatient Gastroenterology Devices Market: Strategic Developments, Partnerships, M&A and Product Launches
TABLE 332: Olympus Corporation: Company Profile
TABLE 333: Boston Scientific Corporation: Company Profile
TABLE 334: Medtronic plc: Company Profile
TABLE 335: FUJIFILM Healthcare Americas Corporation: Company Profile
TABLE 336: PENTAX Medical / HOYA Corporation: Company Profile
TABLE 337: STERIS plc: Company Profile
TABLE 338: Ambu A/S: Company Profile
TABLE 339: Cook Medical: Company Profile
TABLE 340: CONMED Corporation: Company Profile
TABLE 341: KARL STORZ SE & Co. KG: Company Profile
TABLE 342: ERBE Elektromedizin GmbH / ERBE USA: Company Profile
TABLE 343: Micro-Tech Endoscopy USA: Company Profile
TABLE 344: Merit Medical Systems, Inc.: Company Profile
TABLE 345: Ovesco Endoscopy USA: Company Profile
TABLE 346: Creo Medical Group plc: Company Profile
TABLE 347: Laborie Medical Technologies: Company Profile
TABLE 348: Diversatek Healthcare: Company Profile
TABLE 349: CapsoVision, Inc.: Company Profile
TABLE 350: AnX Robotica: Company Profile
TABLE 351: EvoEndo, Inc.: Company Profile
TABLE 352: EndoGastric Solutions, Inc.: Company Profile
TABLE 353: Lumendi Ltd.: Company Profile
TABLE 354: Cosmo Pharmaceuticals / Cosmo Intelligent Medical Devices: Company Profile
TABLE 355: EndoQuest Robotics, Inc.: Company Profile
TABLE 356: U.S. Outpatient Gastroenterology Devices Market: Future Market Scenario Analysis, 2026–2035
TABLE 357: U.S. Outpatient Gastroenterology Devices Market: Disruptive Technologies Impact Matrix
TABLE 358: U.S. Outpatient Gastroenterology Devices Market: AI-Assisted Colonoscopy Adoption Outlook
TABLE 359: U.S. Outpatient Gastroenterology Devices Market: Single-Use Endoscopy Adoption Outlook
TABLE 360: U.S. Outpatient Gastroenterology Devices Market: Advanced Therapeutic Endoscopy Opportunity Analysis
TABLE 361: U.S. Outpatient Gastroenterology Devices Market: Future Procedure Migration to Outpatient Settings
TABLE 362: U.S. Outpatient Gastroenterology Devices Market: Future ASC Infrastructure Expansion
TABLE 363: U.S. Outpatient Gastroenterology Devices Market: Future Endoscopy Installed-Base Replacement Cycle
TABLE 364: U.S. Outpatient Gastroenterology Devices Market: Emerging Business Trends
TABLE 365: U.S. Outpatient Gastroenterology Devices Market: Investment Prioritization and Technology Adoption Roadmap, 2026–2035
TABLE 366: U.S. Outpatient Gastroenterology Devices Market: Strategic Recommendations for Gastroenterology Device Manufacturers
TABLE 367: U.S. Outpatient Gastroenterology Devices Market: Strategic Recommendations for Endoscopy Platform Companies
TABLE 368: U.S. Outpatient Gastroenterology Devices Market: Strategic Recommendations for ASC and HOPD Operators
TABLE 369: U.S. Outpatient Gastroenterology Devices Market: Strategic Recommendations for Gastroenterology Physician Groups
TABLE 370: U.S. Outpatient Gastroenterology Devices Market: Strategic Recommendations for Investors and Private Equity Firms
TABLE 371: U.S. Outpatient Gastroenterology Devices Market: Strategic Recommendations for Distributors and Channel Partners
TABLE 372: U.S. Outpatient Gastroenterology Devices Market: Strategic Recommendations for AI, Digital and Single-Use Endoscopy Companies
TABLE 373: U.S. Outpatient Gastroenterology Devices Market: Strategic Recommendations for New Entrants and Startups
TABLE 374: U.S. Outpatient Gastroenterology Devices Market: Go-to-Market and U.S. State Expansion Strategy
TABLE 375: U.S. Outpatient Gastroenterology Devices Market: Product Positioning, Pricing and Portfolio Expansion Guidance
TABLE 376: U.S. Outpatient Gastroenterology Devices Market: Scope Limitation
TABLE 377: U.S. Outpatient Gastroenterology Devices Market: Data Use Limitation
TABLE 378: U.S. Outpatient Gastroenterology Devices Market: Market Size Estimation Limitation
TABLE 379: U.S. Outpatient Gastroenterology Devices Market: Forecasting Limitation
TABLE 380: U.S. Outpatient Gastroenterology Devices Market: Regulatory and Reimbursement Information Limitation
TABLE 381: U.S. Outpatient Gastroenterology Devices Market: Legal Disclaimer
TABLE 382: U.S. Outpatient Gastroenterology Devices Market: Third-Party Data Disclaimer

List of Figures

FIGURE 1: U.S. Outpatient Gastroenterology Devices Market Segmentation
FIGURE 2: Market Research Methodology
FIGURE 3: Market Ecosystem and Stakeholder Framework
FIGURE 4: Market Attractiveness Analysis
FIGURE 5: Market Dynamics
FIGURE 6: Innovation & Patent Landscape, 2021–2025
FIGURE 7: Outpatient GI Clinical Workflow Economics Framework
FIGURE 8: ASC Capital Procurement Decision Framework
FIGURE 9: Endoscopy Installed-Base Replacement Cycle Framework
FIGURE 10: Procedure Volume–Device Consumption Correlation
FIGURE 11: U.S. Outpatient Gastroenterology Devices Market Size, Historical Trend Analysis, 2021–2024 (US$ Billion)
FIGURE 12: U.S. Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2026–2035 (US$ Billion)
FIGURE 13: U.S. Outpatient Gastroenterology Devices Market Year-wise Growth Curve, 2021–2035
FIGURE 14: PESTEL Analysis
FIGURE 15: Porter’s Five Forces Analysis
FIGURE 16: Value Chain Analysis
FIGURE 17: Supply Chain Analysis
FIGURE 18: AI and Connected Endoscopy Adoption Framework
FIGURE 19: FDA and CMS Regulatory-Reimbursement Framework
FIGURE 20: Infection Prevention and Endoscope Reprocessing Framework
FIGURE 21: ASC Versus HOPD Site-of-Care Economics Framework
FIGURE 22: Product Category Segment Market Share Analysis, 2025 & 2035
FIGURE 23: Product Category Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 24: Endoscopes and Visualization Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 25: Endotherapy and Therapeutic Accessories Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 26: Endoscope Reprocessing and Infection-Prevention Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 27: GI Diagnostic, Capsule and Functional Testing Devices Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 28: AI-Enabled and Digital Endoscopy Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 29: Application Segment Market Share Analysis, 2025 & 2035
FIGURE 30: Application Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 31: Colorectal Cancer Screening, Surveillance and Polyp Management Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 32: Upper Gastrointestinal Diagnosis and Therapy Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 33: Pancreatobiliary and Advanced EUS Procedures Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 34: Inflammatory Bowel Disease, Lower-GI Disorders and GI Bleeding Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 35: Motility Disorders, Metabolic Endoscopy and Other Applications Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 36: End User Segment Market Share Analysis, 2025 & 2035
FIGURE 37: End User Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 38: Gastroenterology-Focused Ambulatory Surgery Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 39: Hospital Outpatient Departments Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 40: Office-Based Gastroenterology Clinics and Physician-Owned Endoscopy Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 41: Academic Medical Center Outpatient Programs and Specialty Referral Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 42: Specialty Diagnostic and Motility Centers Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 43: Technology Type Segment Market Share Analysis, 2025 & 2035
FIGURE 44: Technology Type Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 45: Reusable Flexible Endoscopy Systems Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 46: Single-Use and Disposable Endoscopy Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 47: High-Definition, 4K and Image-Enhanced Endoscopy Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 48: AI-Assisted and Software-Enabled Endoscopy Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 49: Connected Reprocessing, Traceability and Workflow Technologies Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 50: Outpatient Procedure Economics & Procurement Framework
FIGURE 51: Gastroenterology ASC Cost-per-Case Framework
FIGURE 52: Endoscope Lifecycle Cost Structure
FIGURE 53: Endoscope Reprocessing Economics Framework
FIGURE 54: Reusable Versus Single-Use Endoscope Economic Comparison
FIGURE 55: Room Turnover and Endoscopy Suite Throughput Framework
FIGURE 56: Value-Based Procurement Decision Framework
FIGURE 57: Regional Segment Market Share Analysis, 2025 & 2035
FIGURE 58: Regional Segment Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 59: Regional Outpatient GI Procedure Volume and ASC Infrastructure Map
FIGURE 60: West Region U.S. Outpatient Gastroenterology Devices Market Share and Leading Players, 2025
FIGURE 61: West Region Market Share Analysis by State, 2025
FIGURE 62: West Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 63: West Region ASC Infrastructure and Procedure Volume Analysis
FIGURE 64: California Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 65: Washington Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 66: Arizona Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 67: Colorado Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 68: Oregon Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 69: Utah Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 70: Nevada Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 71: New Mexico Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 72: Idaho Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 73: Montana Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 74: Wyoming Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 75: Alaska Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 76: Hawaii Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 77: Northeast Region U.S. Outpatient Gastroenterology Devices Market Share and Leading Players, 2025
FIGURE 78: Northeast Region Market Share Analysis by State, 2025
FIGURE 79: Northeast Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 80: Northeast Region ASC Infrastructure and Procedure Volume Analysis
FIGURE 81: New York Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 82: Massachusetts Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 83: New Jersey Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 84: Pennsylvania Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 85: Connecticut Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 86: Maine Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 87: Vermont Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 88: New Hampshire Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 89: Rhode Island Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 90: Delaware Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 91: South Region U.S. Outpatient Gastroenterology Devices Market Share and Leading Players, 2025
FIGURE 92: South Region Market Share Analysis by State, 2025
FIGURE 93: South Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 94: South Region ASC Infrastructure and Procedure Volume Analysis
FIGURE 95: Texas Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 96: Florida Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 97: Georgia Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 98: North Carolina Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 99: Tennessee Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 100: South Carolina Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 101: Alabama Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 102: Mississippi Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 103: Louisiana Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 104: Arkansas Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 105: Kentucky Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 106: Oklahoma Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 107: Virginia Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 108: Maryland Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 109: West Virginia Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 110: Midwest Region U.S. Outpatient Gastroenterology Devices Market Share and Leading Players, 2025
FIGURE 111: Midwest Region Market Share Analysis by State, 2025
FIGURE 112: Midwest Region Market Size Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 113: Midwest Region ASC Infrastructure and Procedure Volume Analysis
FIGURE 114: Illinois Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 115: Ohio Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 116: Michigan Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 117: Minnesota Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 118: Indiana Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 119: Wisconsin Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 120: Missouri Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 121: Iowa Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 122: Kansas Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 123: Nebraska Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 124: North Dakota Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 125: South Dakota Outpatient Gastroenterology Devices Market Size, Forecast and Trend Analysis, 2021–2035 (US$ Billion)
FIGURE 126: Competitive Landscape; Key Company Market Share Analysis, 2025
FIGURE 127: Company Positioning Matrix
FIGURE 128: Key Player Product Portfolio Benchmarking
FIGURE 129: Strategic Developments, Partnerships, M&A and Product Launches
FIGURE 130: Outpatient Gastroenterology Device Innovation Roadmap
FIGURE 131: AI-Assisted Colonoscopy Adoption Roadmap
FIGURE 132: Single-Use Endoscopy Opportunity Map
FIGURE 133: Advanced Therapeutic Endoscopy Growth Roadmap
FIGURE 134: Connected Reprocessing and Traceability Adoption Roadmap
FIGURE 135: Future Market Scenario Analysis, 2026–2035
FIGURE 136: Disruptive Technologies Impact Matrix
FIGURE 137: Future Outpatient Procedure Migration Framework
FIGURE 138: Future ASC Infrastructure Expansion Map
FIGURE 139: Future Endoscopy Installed-Base Replacement Cycle
FIGURE 140: Emerging Business Trends Matrix
FIGURE 141: Investment Prioritization Matrix
FIGURE 142: Technology Adoption Roadmap, 2026–2035
FIGURE 143: Strategic Growth Roadmap for U.S. Outpatient Gastroenterology Device Companies
FIGURE 144: Go-to-Market and U.S. State Expansion Strategy Framework
FIGURE 145: Product Positioning, Pricing and Portfolio Expansion Framework
FIGURE 146: Report Scope and Disclaimer Framework